[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1146
1. Cohen JL, Jorizzo JL, Kircik LH: Use of a topical emulsion for wound healing. J Support Oncol; 2007 Nov-Dec;5(10 Suppl 5):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of skin trauma following removal of actinic keratoses and skin cancer lesions and following radiation therapy for breast cancer is an often under-treated problem compared to the primary condition.
  • This review will discuss the molecular mechanisms of wound healing and the uses of Biafine in the treatment of skin damage caused by procedures for various conditions such as actinic keratosis, skin cancer lesions, and radiation dermatitis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338743.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biafine; 0 / Emulsions; 0 / Lipids
  • [Number-of-references] 24
  •  go-up   go-down


2. Muehleisen B, Schaerer L, Dummer R, Burg G, Hofbauer GF: Cancer/testis antigen MAGE-A4 expression pattern differs in epithelial skin tumors of organ-transplant recipients and immunocompetent patients. J Cutan Pathol; 2007 Jan;34(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: mAb 57B predominantly recognizing MAGE-A4 was used to stain 119 formalin-fixed, paraffin-embedded epithelial skin tumors (actinic keratosis, bowenoid actinic keratosis, Bowen's disease, and SCC; n = 17, 25, 61, 16, respectively) in immunocompetent patients (n = 84) and OTR (n = 35).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Immunocompetence. Keratosis / metabolism. Neoplasm Proteins / metabolism. Organ Transplantation. Skin Neoplasms / metabolism


3. McIntyre WJ, Downs MR, Bedwell SA: Treatment options for actinic keratoses. Am Fam Physician; 2007 Sep 1;76(5):667-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for actinic keratoses.
  • Actinic keratoses are rough, scaly lesions that commonly occur on sun-exposed areas of the skin.
  • Actinic keratoses are thought to be carcinomas in situ, which can progress to squamous cell carcinomas.
  • Fluorouracil has been the traditional topical treatment for actinic keratoses, although imiquimod 5% cream and diclofenac 3% gel are effective alternative therapies.
  • [MeSH-major] Keratosis / therapy

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am Fam Physician. 2008 Apr 15;77(8):1078-9 [18481555.001]
  • (PMID = 17894135.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 39
  •  go-up   go-down


Advertisement
4. Bellet JS, Kaplan AL, Selim MA, Olsen EA: Keratosis follicularis spinulosa decalvans in a family. J Am Acad Dermatol; 2008 Mar;58(3):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis spinulosa decalvans in a family.
  • Keratosis follicularis spinulosa decalvans (KFSD) is a rare condition characterized by diffuse keratosis pilaris with a scarring alopecia of the scalp and associated photophobia, facial erythema, and palmoplantar keratoderma.
  • Although initially described as a sex-linked disorder, several different inheritance patterns have been observed.
  • [MeSH-major] Darier Disease / genetics. Darier Disease / pathology


5. Issa MC, Piñeiro-Maceira J, Vieira MT, Olej B, Mandarim-de-Lacerda CA, Luiz RR, Manela-Azulay M: Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg; 2010;36(1):39-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Clinical improvement with regard to texture, firmness, wrinkle depth, skin coloration, and clearance of actinic keratoses was observed.

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2010;36(1):49-51 [20002645.001]
  • (PMID = 20002646.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid; 9007-34-5 / Collagen
  •  go-up   go-down


6. Schäfer T, Merkl J, Klemm E, Wichmann HE, Ring J, KORA Study Group: The epidemiology of nevi and signs of skin aging in the adult general population: Results of the KORA-survey 2000. J Invest Dermatol; 2006 Jul;126(7):1490-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ephelides were seen in 16%, lentigines solaris in 62.4%, and lentigines seniles in 33.2%.
  • All signs of skin aging increased significantly with age and so did lentigines solaris, seniles, and actinic keratoses.
  • [MeSH-minor] Adult. Age Distribution. Aged. Cross-Sectional Studies. Data Collection. Ehlers-Danlos Syndrome / epidemiology. Ehlers-Danlos Syndrome / pathology. Female. Germany / epidemiology. Humans. Keratosis / epidemiology. Keratosis / pathology. Lentigo / epidemiology. Lentigo / pathology. Male. Melanoma / epidemiology. Melanoma / pathology. Melanosis / epidemiology. Melanosis / pathology. Middle Aged. Prevalence. Risk Factors. Sex Distribution


7. Ulrich C, Bichel J, Euvrard S, Guidi B, Proby CM, van de Kerkhof PC, Amerio P, Rønnevig J, Slade HB, Stockfleth E: Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol; 2007 Dec;157 Suppl 2:25-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
  • OBJECTIVE: In this study the safety and efficacy of imiquimod 5% cream for the treatments of actinic keratoses in kidney, heart and liver transplant recipients is evaluated.
  • BACKGROUND: Growing populations of organ transplant recipients face increased risk of developing actinic keratosis (AK) and skin cancer secondary to continuous systemic immunosuppressive therapy.
  • Imiquimod 5% cream is an effective option for the treatment of AK, but the safety of topical immune stimulation in immunocompromised patients has not been widely evaluated.
  • CONCLUSIONS: Imiquimod appears to be a safe alternative for the treatment of multiple actinic keratoses in patients with solid organ transplants.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Carcinoma, Squamous Cell / drug therapy. Keratosis / drug therapy. Organ Transplantation. Skin Neoplasms / drug therapy


8. Park MY, Sohn S, Lee ES, Kim YC: Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol; 2010 Jan;62(1):85-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis.
  • METHODS: Fourteen patients with one to three actinic keratoses on the face were treated twice with ALA-PDT by using a 1200 W metal halogen lamp at 1-month intervals.
  • RESULTS: After ALA-PDT, the mean epidermal thickness and dermal inflammatory infiltrate were reduced.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis, Actinic / drug therapy. Photosensitizing Agents / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926165.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / Photosensitizing Agents; 0 / Procollagen; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / Tropoelastin; 0 / fibrillin; 88755TAZ87 / Aminolevulinic Acid; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


9. Dixon A: Treating actinic keratoses with imiquimod. Aust Fam Physician; 2007 May;36(5):341-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating actinic keratoses with imiquimod.
  • Mr KC, 61 years of age, has extensive actinic damage including squamous cell carcinomas (SCCs) and actinic keratoses (AKs) on his face and forehead.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Facial Dermatoses / drug therapy. Keratosis / drug therapy. Photosensitivity Disorders / drug therapy. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492069.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


10. Richtig E, Ahlgrimm-Siess V, Koller S, Gerger A, Horn M, Smolle J, Hofmann-Wellenhof R: Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study. J Eur Acad Dermatol Venereol; 2010 Mar;24(3):293-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follow-up of actinic keratoses after shave biopsy by in-vivo reflectance confocal microscopy--a pilot study.
  • BACKGROUND: Monitoring of treatment efficacy after shave biopsy of actinic keratoses (AK) is often difficult, as clinical and dermoscopic features may not be reliable.
  • OBJECTIVES: We investigated the applicability of in-vivo reflectance confocal microscopy (RCM) for the follow-up of AK after shave biopsy.
  • RESULTS: At baseline all lesions showed typical clinical, dermoscopic and RCM criteria of AK.
  • Three months after shave biopsy, all lesions presented clinically as normal skin (NS), but two lesions showed features suspicious for AK by RCM.
  • After 12 months, one lesion of these two lesions changed into NS in RCM, whereas the other lesion progressed into clinical visible AK.
  • CONCLUSIONS: Our results suggest that RCM might be a useful tool in the follow-up of AK after shave biopsy and might be used in inconclusive clinical and dermoscopic presentations of lesions after surgery or other treatment modalities.
  • [MeSH-major] Biopsy / methods. Keratosis, Actinic / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Disease Progression. Female. Follow-Up Studies. Humans. Male. Pilot Projects. Prognosis. Reproducibility of Results. Severity of Illness Index. Time Factors

  • MedlinePlus Health Information. consumer health - Biopsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732253.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Miteva L, Broshtilova V, Schwartz RA: Verrucous systemic lupus erythematosus. Acta Dermatovenerol Croat; 2009;17(4):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This verrucous variant of lupus erythematosus, sometimes clinically resembling actinic keratosis, keratoacanthoma and squamous cell carcinoma, is reviewed.


12. Kazi TG, Arain MB, Baig JA, Jamali MK, Afridi HI, Jalbani N, Sarfraz RA, Shah AQ, Niaz A: The correlation of arsenic levels in drinking water with the biological samples of skin disorders. Sci Total Environ; 2009 Jan 15;407(3):1019-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2005-2007, a survey was carried out on surface and groundwater arsenic contamination and relationships between As exposure via the drinking water and related adverse health effects (melanosis and keratosis) on villagers resides on the banks of Manchar lake, southern part of Sindh, Pakistan.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027142.001).
  • [ISSN] 0048-9697
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] N712M78A8G / Arsenic
  •  go-up   go-down


13. Faghihi G, Radan M: Xeroderma pigmentosum and lentigo maligna in identical twins. J Dermatolog Treat; 2006;17(4):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, XP presents with early onset cutaneous changes (severe photosensitivity, actinic keratoses, and telangiectasias) and an increase of developing cutaneous malignancies beginning in early childhood, but lentigo maligna and melanomas are relatively rare.

  • Genetic Alliance. consumer health - Xeroderma pigmentosum.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971321.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Jørgensen TM, Tycho A, Mogensen M, Bjerring P, Jemec GB: Machine-learning classification of non-melanoma skin cancers from image features obtained by optical coherence tomography. Skin Res Technol; 2008 Aug;14(3):364-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: A number of publications have suggested that optical coherence tomography (OCT) has the potential for non-invasive diagnosis of skin cancer.
  • We investigated the combined use of several OCT features from basal cell carcinomas (BCC) and actinic keratosis (AK).
  • We studied BCC (41) and AK (37) lesions in 34 consecutive patients.
  • BCCs showed dark globules corresponding to basaloid islands and AKs showed white dots and streaks corresponding to hyperkeratosis.
  • Differences in OCT morphology were not sufficient to differentiate BCC from AK by the naked eye.
  • Machine-learning analysis suggests that when a multiplicity of features is used, correct classification accuracies of 73% (AK) and 81% (BCC) are achieved.
  • CONCLUSION: The data extracted from individual OCT scans included both quantitative and qualitative measures, and at the current level of resolution, these single factors appear insufficient for diagnosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19159385.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


15. Li HY, Xu W, Han DM, Hu R, Hu HY, Hou LZ, Zhang L, Ye JY, Wang J: [Self-assessment characteristics of voice handicap index for voice disorders and its influencing factors]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Feb;44(2):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VHI scores were descending in order among spasmodic dysphonia, vocal fold paralysis, functional dysphonia, sulcus vocalis, benign and malignant tumor of vocal fold, vocal fold cyst, Reinke's edema, vocal fold polyp, vocal fold keratosis and chronic laryngitis, vocal nodule.
  • CONCLUSION: As a useful supplementary instrument to measure the voice disorder severity and the treatment's effect, VHI can comprehensively assess the voice handicap's affect to the life quality and the difference after the treatment, especially in physical, functional and emotional aspects, but it is somehow subject to the educational degree and age.

  • MedlinePlus Health Information. consumer health - Voice Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558882.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Esmann S, Jemec GB: Management of actinic keratosis patients: a qualitative study. J Dermatolog Treat; 2007;18(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of actinic keratosis patients: a qualitative study.
  • OBJECTIVES: In order to reinforce the appropriate UV-related behaviour of patients with actinic keratosis (AK), it is of importance to understand the underlying psychological aspects of having AK.
  • MATERIALS AND METHODS: Open and systematic explorative interviews were conducted with 15 AK patients.
  • Partly based on topics found by the single interviews, two qualitative group interviews (n = 7) with AK patients were performed.
  • RESULTS: Important topics for patients with AK were found to relate to the way to act in the sun (leisure time and outdoor work), a changed appearance, the seriousness of the AK diagnosis, control of the disease, and the sense of illness due to AK.
  • Awareness of these topics is therefore recommended in the management of patient information related to AK.
  • [MeSH-major] Keratosis / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365267.001).
  • [ISSN] 0954-6634
  • [Journal-full-title] The Journal of dermatological treatment
  • [ISO-abbreviation] J Dermatolog Treat
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


17. Makdsi F, Deversa R: Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. Cases J; 2009;2:6946
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report.
  • This combination has not been documented to date to cause an inflammation of a preexisting actinic keratosis.
  • One previous report has described inflammation of AK lesions after the use of docetaxel alone.
  • CASE PRESENTATION: We report a case of a 54-year-old male with a history of untreated actinic keratosis and lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2008 Jun;144(6):779-82 [18559769.001]
  • [Cites] Oncol Rep. 2007 Sep;18(3):581-4 [17671704.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):77-81 [12533171.001]
  • [Cites] J Am Acad Dermatol. 1999 Mar;40(3):367-98; quiz 399-400 [10071309.001]
  • [Cites] Arch Dermatol. 1995 Feb;131(2):202-6 [7857119.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S119-20 [17052530.001]
  • (PMID = 19829884.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740192
  •  go-up   go-down


18. Skiveren J, Haedersdal M, Philipsen PA, Wiegell SR, Wulf HC: Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol; 2006;86(5):409-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study involved 28 patients with actinic keratoses or basal cell carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Carcinoma, Basal Cell / drug therapy. Double-Blind Method. Gels. Humans. Keratosis / drug therapy. Middle Aged. Photosensitivity Disorders / drug therapy. Receptors, Opioid / physiology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16955184.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Gels; 0 / Receptors, Opioid; 0 / methyl 5-aminolevulinate; 76I7G6D29C / Morphine; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


19. Downs AM, Bower CB, Oliver DA, Stone CA: Methyl aminolaevulinate-photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation. Br J Dermatol; 2009 Jul;161(1):189-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methyl aminolaevulinate-photodynamic therapy for actinic keratoses, squamous cell carcinoma in situ and superficial basal cell carcinoma employing a square wave intense pulsed light device for photoactivation.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19416229.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


20. Fuchs A, Marmur E: The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg; 2007 Sep;33(9):1099-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma.
  • BACKGROUND: Actinic keratoses (AKs) are intraepidermal skin tumors that have the potential to progress to squamous cell carcinomas (SCCs).
  • METHODS: To determine the time scale of AK progression, we conducted a retrospective electronic medical record study of all patients diagnosed histopathologically with an SCC between July 1, 2003, and June 30, 2005.
  • RESULTS: Of a total patient population of 6,691, 91 had a histopathologically confirmed diagnosis of an AK at the same site as the subsequent SCC.
  • The length of time for an AK to progress to an SCC was determined to be 24.6 months (95% confidence interval, 21.04-28.16 months).
  • CONCLUSIONS: Although a more controlled in vivo study is indicated, these data provide a good estimate of the time course from an AK to an SCC.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Disease Progression. Humans. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760601.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wolfe CM, Hatfield K, Cognetta AB Jr: Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis. J Drugs Dermatol; 2007 May;6(5):544-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellulitis as a postprocedural complication of topical 5-aminolevulinic acid photodynamic therapy in the treatment of actinic keratosis.
  • BACKGROUND: Actinic keratoses (AKs) are a common premalignant tumor of the skin.
  • [MeSH-minor] Adult. Aged, 80 and over. Face / pathology. Humans. Keratosis / drug therapy. Male. Middle Aged. Skin / microbiology. Skin / pathology

  • MedlinePlus Health Information. consumer health - Cellulitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679192.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


22. Foote JA, Ranger-Moore JR, Einspahr JG, Saboda K, Kenyon J, Warneke J, Miller RC, Goldman R, Xu MJ, Roe DJ, Alberts DS: Chemoprevention of human actinic keratoses by topical DL-alpha-tocopherol. Cancer Prev Res (Phila); 2009 Apr;2(4):394-400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of human actinic keratoses by topical DL-alpha-tocopherol.
  • Contralateral arms of healthy human volunteers with actinic keratoses (AK) were randomly assigned to receive either 12.5% DL-alpha-tocopherol or placebo in a crème base for 6 months.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN E .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Life Sci. 1973 Dec 16;13(12):1635-47 [4591188.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):149-55 [11801552.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Biochimie. 1988 Dec;70(12):1709-13 [3150673.001]
  • [Cites] Nutr Cancer. 1991;15(2):97-106 [2038569.001]
  • [Cites] J Am Acad Dermatol. 1992 May;26(5 Pt 1):744-8 [1583174.001]
  • [Cites] Am J Pathol. 1992 Jul;141(1):139-42 [1352943.001]
  • [Cites] J Cutan Pathol. 1992 Dec;19(6):458-68 [1362576.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):139-44 [8467248.001]
  • [Cites] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777.001]
  • [Cites] Cancer Lett. 1994 Sep 30;85(1):23-9 [7923098.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):343-8 [9162299.001]
  • [Cites] Nutr Cancer. 1996;26(2):183-91 [8875555.001]
  • [Cites] Nutr Cancer. 1996;26(2):193-201 [8875556.001]
  • [Cites] Free Radic Biol Med. 1997;22(3):573-8 [8981051.001]
  • [Cites] Cancer Lett. 1997 Mar 19;114(1-2):203-5 [9103292.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2630-7 [9205069.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1195-202 [9214603.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):583-7 [9264270.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1263-70 [9382565.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1654-9 [9563478.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6 [9591810.001]
  • [Cites] JAMA. 2005 Aug 10;294(6):681-90 [16091570.001]
  • [Cites] J Invest Dermatol. 2008 Dec;128(12):2905-8 [18615112.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] Neoplasia. 1999 Nov;1(5):468-75 [10933063.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001;14 Suppl 1:87-91 [11509912.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1212-7 [11710935.001]
  • [Cites] Biochem Med. 1979 Apr;21(2):168-81 [465013.001]
  • (PMID = 19336724.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / CA-27502
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biogenic Polyamines; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; H4N855PNZ1 / alpha-Tocopherol
  • [Other-IDs] NLM/ NIHMS616770; NLM/ PMC4154592
  •  go-up   go-down


23. Ferran M, Bussaglia E, Matias-Guiu X, Pujol RM: Bilateral and symmetrical palmoplantar punctate keratoses in childhood: a possible clinical clue for an early diagnosis of PTEN hamartoma-tumour syndrome. Clin Exp Dermatol; 2009 Jul;34(5):e28-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral and symmetrical palmoplantar punctate keratoses in childhood: a possible clinical clue for an early diagnosis of PTEN hamartoma-tumour syndrome.
  • Palmoplantar punctate keratoses may be the main cutaneous sign of various diseases (porokeratosis punctata palmaris et plantaris, keratosis punctata of the palmar creases, familial punctate palmoplantar keratoderma) or represent a secondary feature [Cowden's syndrome (CS) and Darier's disease].
  • In CS, such keratoses usually appear during the second and third decades of life, together with other mucocutaneous features.
  • We present the case of a 3-year-old girl with palmoplantar punctate keratoses in whom diagnosis of new-onset CS was suspected only after the development of other cutaneous lesions.
  • Genetic analysis confirmed the diagnosis.
  • This case highlights the necessity to consider CS in the differential diagnosis when palmoplantar punctate keratoses are found, even in paediatric patients.
  • A prompt diagnosis is important in order to monitor the development of possible underlying associated neoplasms.
  • [MeSH-major] Hamartoma Syndrome, Multiple / diagnosis. Keratoderma, Palmoplantar / diagnosis
  • [MeSH-minor] Child, Preschool. Codon, Nonsense. Diagnosis, Differential. Early Diagnosis. Female. Humans. PTEN Phosphohydrolase / genetics. Point Mutation

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508470.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon, Nonsense; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


24. Guha Mazumder DN: Arsenic and non-malignant lung disease. J Environ Sci Health A Tox Hazard Subst Environ Eng; 2007 Oct;42(12):1859-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arsenic and non-malignant lung disease.
  • Characteristic skin lesions (pigmentation, depigmentation and keratosis) are the hallmark signs of chronic arsenic toxicity.
  • Results show evidences of restrictive, obstructive and combined obstructive and restrictive lung disease in different people having chronic lung disease associated with chronic arsenic toxicity.
  • On the basis of clinical study, chest X-ray and HRCT done in Arsenicosis patients with features of chronic lung disease, the abnormalities observed were varied.
  • Evidences of obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis were found in some of the cases.
  • [MeSH-minor] Adult. Bangladesh / epidemiology. Bronchiectasis / chemically induced. Bronchiectasis / epidemiology. Bronchiectasis / pathology. Bronchitis, Chronic / chemically induced. Bronchitis, Chronic / epidemiology. Bronchitis, Chronic / pathology. Environmental Exposure / adverse effects. Environmental Exposure / analysis. Female. Humans. India / epidemiology. Lung Diseases, Interstitial / chemically induced. Lung Diseases, Interstitial / epidemiology. Lung Diseases, Interstitial / pathology. Male. Middle Aged. Odds Ratio. Prevalence. Pulmonary Disease, Chronic Obstructive / chemically induced. Pulmonary Disease, Chronic Obstructive / epidemiology. Pulmonary Disease, Chronic Obstructive / pathology. Skin Diseases / chemically induced. Skin Diseases / epidemiology. Skin Diseases / pathology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952787.001).
  • [ISSN] 1093-4529
  • [Journal-full-title] Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering
  • [ISO-abbreviation] J Environ Sci Health A Tox Hazard Subst Environ Eng
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical; N712M78A8G / Arsenic
  •  go-up   go-down


25. Lee WJ, Park GH, Lee MW, Choi JH, Moon KC, Koh JK: Keratosis follicularis and dermatomyositis: is there a common pathogenesis? J Eur Acad Dermatol Venereol; 2009 Aug;23(8):977-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Keratosis follicularis and dermatomyositis: is there a common pathogenesis?
  • [MeSH-major] Darier Disease / etiology. Dermatomyositis / etiology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Darier Disease.
  • Genetic Alliance. consumer health - Dermatomyositis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210696.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


26. West DA, Aires DJ: Treatment of actinic keratoses with topical fluorouracil. Am Fam Physician; 2010 May 15;81(10):1186
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of actinic keratoses with topical fluorouracil.
  • [MeSH-major] Antimetabolites / therapeutic use. Fluorouracil / therapeutic use. Keratosis, Actinic / drug therapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507040.001).
  • [ISSN] 1532-0650
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; U3P01618RT / Fluorouracil
  •  go-up   go-down


27. Korde VR, Bonnema GT, Xu W, Krishnamurthy C, Ranger-Moore J, Saboda K, Slayton LD, Salasche SJ, Warneke JA, Alberts DS, Barton JK: Using optical coherence tomography to evaluate skin sun damage and precancer. Lasers Surg Med; 2007 Oct;39(9):687-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Optical coherence tomography (OCT) is a depth resolved imaging modality that may aid in identifying sun damaged skin and the precancerous condition actinic keratosis (AK).
  • Each site received a dermatological evaluation, a histological diagnosis, and a solar elastosis (SE) score.
  • RESULTS: Characteristic OCT image features were identified of sun protected, undiseased, sun damaged, and AK skin.
  • A statistically significant difference (P<0.0001) between the average attenuation values of skin with minimal and severe solar elastosis was observed.
  • Significant differences (P<0.0001) were also found between undiseased skin and AK using a gradient analysis.
  • Using image features, AK could be distinguished from undiseased skin with 86% sensitivity and 83% specificity.
  • CONCLUSION: OCT has the potential to guide biopsies and provide non-invasive measures of skin sun damage and disease state, possibly increasing efficiency of chemopreventive agent trials.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):4-7 [10607349.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):11-7 [10607351.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):42-8 [10863222.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1292-7 [10882869.001]
  • [Cites] J Biomed Opt. 2003 Jul;8(3):570-5 [12880366.001]
  • [Cites] Arch Dermatol Res. 2003 Jun;295(2):50-5 [12682851.001]
  • [Cites] J Dermatol Sci. 2005 Nov;40(2):85-94 [16139481.001]
  • [Cites] J Biomed Opt. 2004 Mar-Apr;9(2):274-81 [15065891.001]
  • [Cites] Skin Res Technol. 2004 Aug;10(3):169-73 [15225266.001]
  • [Cites] Int J Dermatol. 1984 Jun;23(5):322-9 [6746182.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):946-52 [7769264.001]
  • [Cites] J Am Acad Dermatol. 1997 Dec;37(6):958-63 [9418764.001]
  • [Cites] Clin Exp Dermatol. 2005 Jan;30(1):79-82 [15663511.001]
  • [Cites] Technol Cancer Res Treat. 2003 Dec;2(6):525-35 [14640764.001]
  • (PMID = 17960754.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502-24S1; United States / NCI NIH HHS / CA / P01 CA027502-25; United States / NIBIB NIH HHS / EB / T32 EB000809-04; United States / NIBIB NIH HHS / EB / T32 EB000809-01; United States / NCI NIH HHS / CA / CA027502-21; United States / NCI NIH HHS / CA / CA027502-24; United States / NCI NIH HHS / CA / CA027502-20; United States / NCI NIH HHS / CA / CA027502-20S1; United States / NIBIB NIH HHS / EB / T32 EB000809-05; United States / NIBIB NIH HHS / EB / EB000809-04; United States / NCI NIH HHS / CA / P01 CA27502; United States / NCI NIH HHS / CA / P01 CA027502-20S1; United States / NIBIB NIH HHS / EB / EB000809-01; United States / NCI NIH HHS / CA / CA027502-24S1; United States / NCI NIH HHS / CA / P01 CA027502-24; United States / NIBIB NIH HHS / EB / T32 EB000809-02; United States / NCI NIH HHS / CA / CA027502-25S1; United States / NIBIB NIH HHS / EB / T32 EB000809; United States / NCI NIH HHS / CA / CA027502-25; United States / NCI NIH HHS / CA / P01 CA027502-19; United States / NIBIB NIH HHS / EB / EB000809-02; United States / NCI NIH HHS / CA / CA027502-22; United States / NCI NIH HHS / CA / P01 CA027502-26; United States / NCI NIH HHS / CA / P01 CA027502-20; United States / NCI NIH HHS / CA / CA027502-23A1; United States / NIBIB NIH HHS / EB / EB000809-03; United States / NIBIB NIH HHS / EB / T32 EB000809-03; United States / NCI NIH HHS / CA / P01 CA027502-22; United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P01 CA027502-21; United States / NCI NIH HHS / CA / P01 CA027502-25S1; United States / NIBIB NIH HHS / EB / EB000809-05; United States / NCI NIH HHS / CA / P01 CA027502-23A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS48080; NLM/ PMC2397550
  •  go-up   go-down


28. King SC, Chen S: Analyzing the cost of preventing nonmelanoma skin cancer. J Invest Dermatol; 2009 Dec;129(12):2745-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue, Gordon et al. report a novel study evaluating the cost-effectiveness of promoting sunscreen use to prevent actinic keratoses and nonmelanoma skin cancer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Invest Dermatol. 2009 Dec;129(12):2766-71 [19536149.001]
  • (PMID = 19901945.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  •  go-up   go-down


29. Arai E, Shimizu M, Tsuchida T, Izaki S, Ogawa F, Hirose T: Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases. Arch Dermatol; 2007 Jan;143(1):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases.
  • OBJECTIVE: To provide evidence that lymphomatoid keratosis should be categorized as an epidermotropic subtype of cutaneous lymphoid hyperplasia.
  • DESIGN: Clinicopathological, immunohistochemical, and molecular biological studies of epidermotropic and dermal bandlike infiltrates of lymphocytes without necrotic keratinocytes, Civatte bodies, or Max-Joseph spaces and solar lentigo or seborrheic keratosis adjacent to the lesion, but with epidermal hyperplastic change (clinically scaly plaque) in cases of lymphomatoid keratosis.
  • CONCLUSIONS: Our results indicate that lymphomatoid keratosis is a clinically benign keratotic lesion but histologically malignant, simulating mycosis fungoides.
  • Therefore, "lymphomatoid" keratosis should be classed as a pseudolymphoma, namely, a subtype of cutaneous lymphoid hyperplasia with epidermotropism.
  • [MeSH-major] Gene Rearrangement. Keratosis / pathology. Pseudolymphoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD20. Antigens, CD79. B-Lymphocytes / immunology. CD4-CD8 Ratio. Diagnosis, Differential. Female. Genes, T-Cell Receptor beta. Genes, T-Cell Receptor gamma. Humans. Immunohistochemistry. Japan. Male. Medical Records. Middle Aged. Molecular Biology. Polymerase Chain Reaction. Retrospective Studies. T-Lymphocytes / immunology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224542.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79
  •  go-up   go-down


30. Al-Waili NS, Butler GJ: Phototherapy and malignancy: possible enhancement by iron administration and hyperbaric oxygen. Med Hypotheses; 2006;67(5):1148-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PDT with ALA is used for treatment of actinic keratosis (AK).

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860490.001).
  • [ISSN] 1532-2777
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Reactive Oxygen Species; 42VZT0U6YR / Heme; 88755TAZ87 / Aminolevulinic Acid; E1UOL152H7 / Iron; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


31. Fernandez-Flores A: Irritated seborrheic keratosis with coarse keratohyalin granules. Rom J Morphol Embryol; 2009;50(4):583-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irritated seborrheic keratosis with coarse keratohyalin granules.
  • AIMS: The viral etiology of certain types of seborrheic keratosis (SK) has been a controversial subject in literature, with different molecular results.
  • On the contrary, to the molecular approach, some have suggested that certain types of SK are indeed warts, due to their morphologic features.
  • We decided to investigate the presence of coarse keratohyalin granules in cases of irritated SK.
  • MATERIAL, METHODS AND RESULTS: We examined the last 60 cases with such a diagnosis in our Service of Anatomic Pathology and found these granules in eight cases (7.5%).
  • In these eight cases, we also looked for other morphologic signs suggesting a viral origin, such as papilated, exo-endophytic configuration, parakeratosis at the tips of digitations, dilated vessels in the papillae and koilocytes.
  • CONCLUSIONS: We discuss the meaning of such a finding as described in literature, and conclude that it should be a specific feature to look out for, in cases of irritated SK, in order to exclude a diagnosis of verruca vulgaris.
  • [MeSH-major] Cytoplasmic Granules / pathology. Keratins / metabolism. Keratosis, Seborrheic / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epidermis / metabolism. Epidermis / pathology. Epidermis / virology. Female. Humans. Male. Middle Aged. Parakeratosis / metabolism. Parakeratosis / pathology. Parakeratosis / virology. Warts / pathology. Warts / virology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942951.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / keratohyalin; 68238-35-7 / Keratins
  •  go-up   go-down


32. Patel MJ, Ulrich C, Forschner T: Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses. Br J Dermatol; 2007 May;156 Suppl 3:57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses.
  • Diclofenac 3% gel is an effective treatment for actinic keratoses (AKs) and is reported to be generally well tolerated with only mild local reactions.
  • This raises the question as to whether there is a subset of patients with skin cancer or AK lesions that are highly/more susceptible to local reactions caused by cyclo-oxygenase-2 (COX-2) inhibitors and peroxisome proliferator-activated receptor (PPAR) agonists?
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Cyclooxygenase 2 Inhibitors / adverse effects. Diclofenac / adverse effects. Drug Eruptions / genetics. Keratosis / drug therapy. Peroxisome Proliferator-Activated Receptors / genetics

  • Hazardous Substances Data Bank. DICLOFENAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488409.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Gels; 0 / Peroxisome Proliferator-Activated Receptors; 144O8QL0L1 / Diclofenac
  •  go-up   go-down


33. Fanti PA, Dika E, Vaccari S, Miscial C, Varotti C: Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol; 2006 Dec;45(12):1464-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod.
  • [MeSH-major] Aminoquinolines / adverse effects. Keratosis / drug therapy. Psoriasis / chemically induced

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184267.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


34. Heal CF, Weedon D, Raasch BA, Hill BT, Buettner PG: Agreement between histological diagnosis of skin lesions by histopathologists and a dermato-histopathologist. Int J Dermatol; 2009 Dec;48(12):1366-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Agreement between histological diagnosis of skin lesions by histopathologists and a dermato-histopathologist.
  • It is important that doctors are able to diagnose skin lesions accurately, and this is supported by accurate histological diagnosis.
  • OBJECTIVE: To compare agreement for histological diagnosis between local histopathologists with a dermato-histopathologist from a stratified random sample of excised skin lesions derived from a set of epidemiological data.
  • Results Positive predictive values (PPVs) for the primary histological diagnosis were above 90% for basal cell carcinoma, cutaneous melanoma, and common naevus.
  • DISCUSSION: Lack of agreement between histopathologists regarding the diagnosis of SCC and actinic keratosis has been previously recognized in the literature and this is again reflected in our study.
  • [MeSH-minor] Dermatology. Diagnostic Errors / statistics & numerical data. Humans. Keratosis, Actinic / pathology. Pathology, Clinical. Predictive Value of Tests


35. Engel F, Ellero B, Woehl-Jaegle ML, Cribier B: [Diffuse sebaceous hyperplasia of the face induced by cyclosporine]. Ann Dermatol Venereol; 2005 Apr;132(4):342-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypertrichosis, follicular keratosis, acne and folliculitis are very common.
  • The histological analysis confirmed the diagnosis of sebaceous hyperplasia.

  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886561.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


36. Borenstein M, Mirzabeigi M, Vincek V: Pityrosporum and seborrheic keratosis: an association. Dermatol Online J; 2005;11(2):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pityrosporum and seborrheic keratosis: an association.
  • Seborrheic keratoses (SK) are one of the most common benign tumors of the skin.
  • Studies have suggested that human papillomavirus or a benign clonal proliferation of epidermal cells is involved in the pathogenesis of some SK's, however, this issue remains to be resolved.
  • Pityrosporum ovale has been implicated in the pathogenesis of seborrheic dermatitis, however, its potential role in association with SK's has not been evaluated as evidenced by the fact that there are no publications in the English-language literature regarding this issue.
  • We observed a common occurrence of Pityrosporum organisms in the stratum corneum of SK on routine histopathologic sections and decided to investigate whether there was an association between these two common entities.
  • We found that in a majority of the SK studied Pityrosporum was present, which was significantly different from controls (verruca vulgaris and basal cell carcinoma).
  • [MeSH-major] Dermatomycoses / complications. Keratosis, Seborrheic / etiology. Keratosis, Seborrheic / microbiology. Malassezia / isolation & purification

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150211.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Heppt W: [Skin tumors in facial plastic surgery]. HNO; 2009 Apr;57(4):324-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histologic findings are actinic keratosis and basal cell carcinoma.
  • [MeSH-major] Facial Neoplasms / diagnosis. Facial Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / trends. Reconstructive Surgical Procedures / trends. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Feb;99(2):136-41 [15660081.001]
  • [Cites] Laryngoscope. 1990 Mar;100(3):313-9 [2308457.001]
  • [Cites] HNO. 1998 Jun;46(6):569-78 [9677488.001]
  • [Cites] Plast Reconstr Surg. 2008 Jul;122(1):240-3 [18594411.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Dec;4(12):1080-4 [17176417.001]
  • [Cites] HNO. 2007 Jun;55(6):497-510 [17486306.001]
  • [Cites] Klin Monbl Augenheilkd. 1988 Dec;193(6):647-50 [3065572.001]
  • [Cites] Plast Reconstr Surg. 1967 May;39(5):472-7 [5336914.001]
  • [Cites] Plast Reconstr Surg. 2007 Oct;120(5):1171-207; discussion 1208-16 [17898591.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 Aug;221(8):609-14 [15343443.001]
  • [Cites] Br J Plast Surg. 1962 Jul;15:242-54 [13871292.001]
  • [Cites] Adv Exp Med Biol. 2008;624:89-103 [18348450.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):144-8 [9754642.001]
  • [Cites] Plast Reconstr Surg. 2008 Feb;121(2):458-65 [18300962.001]
  • [Cites] GMS Curr Top Otorhinolaryngol Head Neck Surg. 2007;6:Doc02 [22073078.001]
  • [Cites] Dermatol Surg. 2000 Mar;26(3):215-8 [10759796.001]
  • [Cites] Langenbecks Arch Surg. 2000 Jul;385(4):284-9 [10958513.001]
  • (PMID = 19347378.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


38. Ferrara G, Zalaudek I, Cabo H, Soyer HP, Argenziano G: Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology? Clin Exp Dermatol; 2005 Sep;30(5):586-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision of basal cell carcinoma with seborrhoeic keratosis: a dermoscopic aid to histopathology?
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Clin Exp Dermatol. 2004 Mar;29(2):199-200 [14987284.001]
  • (PMID = 16045704.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


39. Ortonne JP, Queille-Roussel C, Duteil L: 3% diclofenac in 2.5% hyaluronic acid (Solaraze) does not induce photosensitivity or phototoxicity alone or in combination with sunscreens. Eur J Dermatol; 2006 Jul-Aug;16(4):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Topical treatment with 3% diclofenac in 2.5% hyaluronic acid (Solaraze) has been extensively documented for the treatment of actinic keratoses (AK).
  • Since sun protection is a vital part of AK management, two Phase IV studies were carried out to investigate the phototoxicity and photosensitisation potential of 3% diclofenac in 2.5% hyaluronic acid in combination with sunscreens.

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935795.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drug Combinations; 0 / Sunscreening Agents; 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


40. Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, Nordin P, Stenquist B, Kirnbauer R, Dillner J, de Villiers EM, Viraskin Study Group: Cutaneous human papillomaviruses found in sun-exposed skin: Beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis; 2007 Sep 15;196(6):876-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We studied 349 nonimmunosuppressed patients with skin lesions (82 with squamous cell carcinomas, 126 with basal cell carcinomas, 49 with actinic keratoses, and 92 with benign lesions).
  • RESULTS: Overall, 12% of healthy skin samples were positive for HPV DNA, compared with 26% of benign lesions, 22% of actinic keratoses, 18% of basal cell carcinomas, and 26% of squamous cell carcinomas.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol Methods. 2003 Jun 30;110(2):129-36 [12798239.001]
  • [Cites] J Gen Virol. 2007 May;88(Pt 5):1479-83 [17412976.001]
  • [Cites] Br J Dermatol. 2003 Jul;149(1):64-73 [12890196.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7515-9 [14612553.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):388-94 [15245440.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):18-22 [10607352.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):561-6 [10662801.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):592-8 [10698529.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):281-8 [10861634.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):289-97 [10861635.001]
  • [Cites] J Invest Dermatol. 2000 Jul;115(1):124-8 [10886519.001]
  • [Cites] Br J Dermatol. 2000 Sep;143(3):513-9 [10971322.001]
  • [Cites] J Virol. 2000 Dec;74(24):11636-41 [11090162.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):828-34 [11275987.001]
  • [Cites] Photochem Photobiol. 2001 Jul;74(1):108-14 [11460531.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1244-5 [11751241.001]
  • [Cites] Cancer Detect Prev. 2001;25(6):533-47 [12132874.001]
  • [Cites] J Virol. 2003 Feb;77(3):2195-206 [12525654.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2509-14 [12791874.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Sep;18(5):552-5 [15324391.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] Virology. 1989 Sep;172(1):73-81 [2549724.001]
  • [Cites] Obstet Gynecol. 1992 Mar;79(3):328-37 [1310805.001]
  • [Cites] Cancer Res. 1993 Nov 1;53(21):5328-33 [8221669.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:157-75 [8205840.001]
  • [Cites] J Clin Microbiol. 1995 Mar;33(3):690-5 [7751378.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):802-11 [8637046.001]
  • [Cites] J Invest Dermatol. 1997 May;108(5):712-5 [9129220.001]
  • [Cites] J Photochem Photobiol B. 1997 Aug;40(1):29-47 [9301042.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):356-61 [9359482.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):752-5 [9579540.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):843-4 [10411160.001]
  • [Cites] J Gen Virol. 1999 Sep;80 ( Pt 9):2437-43 [10501499.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5359-69 [10508168.001]
  • [Cites] Br J Dermatol. 2004 Nov;151(5):1060-5 [15541085.001]
  • [Cites] Cutis. 2004 Nov;74(5 Suppl):14-8 [15603217.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):93-7 [15982308.001]
  • [Cites] J Pathol. 2006 Jan;208(2):165-75 [16362995.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1073-7 [16557595.001]
  • [Cites] J Gen Virol. 2003 Jul;84(Pt 7):1881-6 [12810883.001]
  • (PMID = 17703418.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18990
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ EMS55140; NLM/ PMC3795387
  •  go-up   go-down


41. Zalaudek I, Giacomel J, Argenziano G, Hofmann-Wellenhof R, Micantonio T, Di Stefani A, Oliviero M, Rabinovitz H, Soyer HP, Peris K: Dermoscopy of facial nonpigmented actinic keratosis. Br J Dermatol; 2006 Nov;155(5):951-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy of facial nonpigmented actinic keratosis.
  • BACKGROUND: The accuracy of clinical diagnosis of nonpigmented, facial actinic keratosis (AK) is often suboptimal, even for experienced clinicians.
  • OBJECTIVES: To investigate the dermoscopic features of nonpigmented AK located on the head/neck that may assist the clinical diagnosis.
  • RESULTS: Four essential dermoscopic features were observed in facial AK: (i) erythema, revealing a marked pink-to-red 'pseudonetwork' surrounding the hair follicles (95%);.
  • CONCLUSIONS: A dermoscopic model of 'strawberry' pattern is presented, which may prove helpful in the in vivo diagnosis of nonpigmented, facial AK.
  • [MeSH-major] Dermoscopy / methods. Facial Dermatoses / diagnosis. Keratosis / diagnosis. Photosensitivity Disorders / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034524.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


42. Astner S, Dietterle S, Otberg N, Röwert-Huber HJ, Stockfleth E, Lademann J: Clinical applicability of in vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of nonmelanoma skin cancer. J Biomed Opt; 2008 Jan-Feb;13(1):014003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applicability of in vivo fluorescence confocal microscopy for noninvasive diagnosis and therapeutic monitoring of nonmelanoma skin cancer.
  • However, there is increasing interest in the development of noninvasive optical technologies for evaluation, diagnosis, and monitoring of skin disease in vivo.
  • Fluorescent confocal microscopy is an innovative optical technology that has previously been used for morphologic evaluation of live human tissue.
  • Skin sites of 10 participants with no prior history of skin disease served as controls and to evaluate topographic variations of normal skin in vivo.
  • Thirty patients with a suspected diagnosis of nonmelanoma skin cancer were evaluated, whereby FLSM features of actinic keratoses (AK) and basal cell carcinoma (BCC) were recorded in an observational analysis.
  • Common FLSM features to AK and BCC included nuclear pleomorphism at the level of the granular and spinous layer and increased vascularity in the superficial dermal compartment.
  • Even though the presence of superficial disruption and mere atypia of epidermal keratinocytes was more indicative of AK, the nesting of atypical basal cells, increased blood vessel tortuosity, and nuclear polarization were more typical for BCC.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315361.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


43. Acar B, Babademez MA, Karabulut H, Karasen RM: An unusual cause of dysphonia: laryngeal verruca vulgaris. B-ENT; 2009;5(3):183-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The patient was disease-free up to 1 year and 6 months after surgery.
  • CONCLUSIONS: We described histopathological features of VVL that will facilitate its distinction from laryngeal keratosis, squamous papillomas, verrucous hyperplasia, and verrucous carcinoma.

  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902857.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


44. Liu H, Chen S, Zhang F, Shi B, Shi Z, Zhang D, Yu M, Tian H, Yang B: Seborrheic keratosis or verruca plana? A pilot study with confocal laser scanning microscopy. Skin Res Technol; 2010 Nov;16(4):408-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosis or verruca plana? A pilot study with confocal laser scanning microscopy.
  • BACKGROUND: Differentiation of some seborrheic keratosis (SK) and verruca plana (VP) lesions is a challenge.
  • Confocal laser scanning microscopy (CLSM) has been proved to be useful in the diagnosis of skin diseases; however, to date, there is no report on the differential study of the two diseases with CLSM.
  • OBJECTIVES: To obtain the CLSM image characteristics of SK and VP, and then test the differential ability of CLSM imaging.
  • METHODS: We recruited 10 patients with typical lesions of SK under CLSM images to validate the features reported.
  • All the cases with lesions suggestive of SK or VP were advised to undergo imaging with CLSM, and if CLSM imaging reflected discordantly with the clinical diagnosis, a biopsy was suggested for the exact lesion imaged.
  • Finally, two clinical dermatologists, who had no previous experience with CLSM, were tested with the simplified features of CLSM images to differentiate the suspected lesions of SK and VP among the cases collected.
  • RESULTS: In total, there were 58 cases with CLSM images and histology results collected, in which, 40 cases were diagnosed as SK and 18 cases as VP by histology.
  • CONCLUSION: CLSM proved to be valuable in the differential diagnosis of SK and VP.
  • [MeSH-major] Dermoscopy / methods. Keratosis, Seborrheic / pathology. Microscopy, Confocal / methods. Warts / pathology
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Pilot Projects. Prospective Studies. Skin / pathology

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 21039905.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


45. Wollina U, Abdel-Naser MB, Verma S: Skin physiology and textiles - consideration of basic interactions. Curr Probl Dermatol; 2006;33:1-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mechanical properties like roughness of fabric surface are responsible for non-specific skin reactions like wool intolerance or keratosis follicularis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766877.001).
  • [ISSN] 1421-5721
  • [Journal-full-title] Current problems in dermatology
  • [ISO-abbreviation] Curr. Probl. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  • [Number-of-references] 78
  •  go-up   go-down


46. Mukherjee SC, Saha KC, Pati S, Dutta RN, Rahman MM, Sengupta MK, Ahamed S, Lodh D, Das B, Hossain MA, Nayak B, Mukherjee A, Chakraborti D, Dulta SK, Palit SK, Kaies I, Barua AK, Asad KA: Murshidabad--one of the nine groundwater arsenic-affected districts of West Bengal, India. Part II: dermatological, neurological, and obstetric findings. Clin Toxicol (Phila); 2005;43(7):835-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of 2595 children we examined for arsenical skin lesions, 122 (4%) were registered with arsenical skin lesions, melanosis with or without keratosis.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440511.001).
  • [ISSN] 1556-3650
  • [Journal-full-title] Clinical toxicology (Philadelphia, Pa.)
  • [ISO-abbreviation] Clin Toxicol (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Water Pollutants, Chemical
  •  go-up   go-down


47. Patel KS, Shrivas K, Brandt R, Jakubowski N, Corns W, Hoffmann P: Arsenic contamination in water, soil, sediment and rice of central India. Environ Geochem Health; 2005 Apr;27(2):131-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most of people living in this region are suffering with arsenic borne diseases (i.e. melanosis, keratosis, skin cancer, etc.).

  • MedlinePlus Health Information. consumer health - Arsenic.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Pollut. 1990;64(2):143-53 [15092299.001]
  • [Cites] Sci Total Environ. 2003 Jun 1;308(1-3):15-35 [12738198.001]
  • [Cites] Environ Sci Technol. 2001 Jul 1;35(13):2621-6 [11452583.001]
  • [Cites] Environ Health Perspect. 2001 Mar;109(3):245-51 [11333185.001]
  • [Cites] Environ Health Perspect. 1999 May;107(5):359-65 [10210691.001]
  • [Cites] Environ Health Perspect. 2003 Jul;111(9):1194-201 [12842773.001]
  • [Cites] Environ Sci Technol. 1994 May 1;28(5):877-81 [22191829.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Hypertension. 1995 Jan;25(1):53-60 [7843753.001]
  • [Cites] Am J Epidemiol. 1998 Jul 15;148(2):198-203 [9676702.001]
  • [Cites] Chemosphere. 2002 Nov;49(6):605-18 [12430648.001]
  • [Cites] Am J Epidemiol. 1989 Dec;130(6):1123-32 [2589305.001]
  • [Cites] Mol Cell Biochem. 2001 Jun;222(1-2):137-40 [11678595.001]
  • [Cites] Environ Sci Technol. 2002 Mar 1;36(5):962-8 [11918027.001]
  • [Cites] Environ Int. 2004 May;30(3):383-7 [14987870.001]
  • [Cites] Indian J Environ Health. 2002 Jul;44(3):238-43 [14503449.001]
  • (PMID = 16003581.001).
  • [ISSN] 0269-4042
  • [Journal-full-title] Environmental geochemistry and health
  • [ISO-abbreviation] Environ Geochem Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Metals; 0 / Soil Pollutants; 0 / Water Pollutants; N712M78A8G / Arsenic
  •  go-up   go-down


48. Ntomouchtsis A, Karakinaris G, Poulolpoulos A, Kechagias N, Kittikidou K, Tsompanidou C, Vahtsevanos K, Antoniades K: Benign lip lesions. A 10-year retrospective study. Oral Maxillofac Surg; 2010 Jun;14(2):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 24 cases of actinic keratosis were added in the latter group.
  • RESULTS: Of the benign lesions, the commonest were haemangiomas (19.28%), actinic keratosis (17.14%), intradermal naevus (14.28%), fibroma (9.28%), papilloma (7.85%), mild and moderate dysplasia (7.85%) and mucocele (7.14%).
  • Accurate auditing and detailed statistical analysis aid in disease prevention and help avoid errors in diagnosis and management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 1990 Jul-Aug;12(4):316-20 [2193904.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 Sep;62(3):284-91 [3462634.001]
  • [Cites] Int J Paediatr Dent. 2006 Jan;16(1):31-9 [16364090.001]
  • [Cites] Community Dent Oral Epidemiol. 1980 Feb;8(1):1-26 [6929240.001]
  • [Cites] J Clin Pediatr Dent. 2000 Winter;24(2):133-5 [11314322.001]
  • [Cites] Dent Clin North Am. 2005 Jan;49(1):223-40, x [15567370.001]
  • [Cites] Int J Paediatr Dent. 2005 Mar;15(2):89-97 [15790365.001]
  • [Cites] J Am Dent Assoc. 2004 Sep;135(9):1279-86 [15493392.001]
  • [Cites] Community Dent Oral Epidemiol. 1991 Jun;19(3):129-40 [1864064.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Oct;88(4):469-72 [10519757.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2005 Nov-Dec;10(5):376-87 [16264385.001]
  • [Cites] J Am Dent Assoc. 2008 May;139(5):587-90 [18451375.001]
  • (PMID = 20112123.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


49. Woodmansee C, Pillow J, Skinner RB Jr: The role of topical immune response modifiers in skin cancer. Drugs; 2006;66(13):1657-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 May;122(5):1266-76 [15140231.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:59-61 [14616354.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Dec;47(12):3846-52 [14638493.001]
  • [Cites] Dermatol Surg. 2003 Oct;29(10 ):1027-34 [12974699.001]
  • [Cites] J Am Acad Dermatol. 2001 Mar;44(3):462-70 [11209116.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:66-70 [14616356.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):497-501 [12271290.001]
  • [Cites] Dermatol Surg. 2004 Aug;30(8):1101-12 [15274700.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):510-4 [15837872.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S229-35 [12271284.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):571-7 [12271303.001]
  • [Cites] J Am Acad Dermatol. 2000 Sep;43(3):555-6 [10954675.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):945-7 [12873904.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] N Engl J Med. 1992 Dec 3;327(23):1649-62 [1435901.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Dermatol Surg. 2005 Jun;31(6):659-64 [15996416.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] J Drugs Dermatol. 2003 Jan;2(1):73-6 [12852386.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S225-8 [12271283.001]
  • [Cites] Arch Dermatol. 2003 Mar;139(3):273-6 [12622616.001]
  • [Cites] Arch Dermatol. 2001 Jan;137(1):14-6 [11176654.001]
  • [Cites] Arch Dermatol. 2004 Dec;140(12 ):1542 [15611446.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] Br J Dermatol. 2001 Dec;145(6):1022-3 [11899127.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):545-8 [11907505.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] Br J Dermatol. 2000 Oct;143(4):843-5 [11069469.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):807-13 [11312429.001]
  • (PMID = 16978032.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Imidazoles; 0 / Toll-Like Receptors; P1QW714R7M / imiquimod; V3DMU7PVXF / resiquimod
  • [Number-of-references] 35
  •  go-up   go-down


50. Del Rosso JQ: The use of topical imiquimod for the treatment of actinic keratosis: a status report. Cutis; 2005 Oct;76(4):241-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of topical imiquimod for the treatment of actinic keratosis: a status report.
  • Topical imiquimod 5% cream is approved for the treatment of actinic keratosis (AK), superficial basal cell carcinoma, and external genital warts.
  • This article reviews available data on the use of topical imiquimod for AK.
  • Topical imiquimod is an effective and safe treatment option for AK that produces complete eradication or marked reduction in the number of lesions in most patients.
  • Recent evidence suggests that many patients who effectively are cleared of AK lesions after topical imiquimod use remain free of lesions for several months to 2 years or develop a minimal number of new AK lesions.
  • [MeSH-major] Aminoquinolines / therapeutic use. Keratosis / drug therapy

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315560.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  • [Number-of-references] 39
  •  go-up   go-down


51. Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Laffitte E, Lapointe AC, Pascual M, Pelloni F, Serra A, SGDV working group for organ transplant recipients: Swiss clinical practice guidelines for skin cancer in organ transplant recipients. Swiss Med Wkly; 2009 Jul 25;139(29-30):407-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Once transplanted, SOTRs should be seen by a dermatologist yearly for repeat education as well as early diagnosis, prevention and treatment of skin cancer.
  • Cumulative sun damage results in field cancerisation with numerous in-situ SCC such as actinic keratosis and Bowen's disease which should be treated proactively.


52. Deprez M, Uffer S: Clinicopathological features of eyelid skin tumors. A retrospective study of 5504 cases and review of literature. Am J Dermatopathol; 2009 May;31(3):256-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign tumors largely predominated over malignant ones, representing 84% of cases in this series, and the 5 most frequent subtypes were squamous cell papilloma (26%), seborrheic keratosis (21%), melanocytic nevus (20%), hidrocystoma (8%), and xanthoma/xanthelasma (6%).
  • For several tumor subtypes, there was a poor correlation between clinical and histological diagnosis, stressing the numerous pitfalls in the diagnosis of eyelid tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Child. Child, Preschool. Female. Hidrocystoma / pathology. Humans. Infant. Keratosis, Seborrheic / pathology. Male. Middle Aged. Nevus, Pigmented / pathology. Papilloma / pathology. Predictive Value of Tests. Retrospective Studies. Sebaceous Gland Neoplasms / pathology. Skin Neoplasms / pathology. Sweat Gland Neoplasms / pathology. Xanthomatosis / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384066.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


53. Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J: Seborrheic keratosislike melanoma with folliculotropism. Arch Dermatol; 2007 Mar;143(3):373-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBSERVATIONS: A 34-year-old man was seen for a conspicuous pigmented lesion on his back that clinically resembled a seborrheic keratosis because of the presence of multiple comedolike openings.
  • [MeSH-minor] Adult. Humans. Keratosis, Seborrheic / pathology. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372102.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Rossi R, Calzavara-Pinton PG, Giannetti A, Peserico A, Santucci M, Vena GA, Lotti T: Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol; 2009 Dec;144(6):713-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Italian guidelines and therapeutic algorithm for actinic keratoses.
  • The prevalence of actinic keratosis (AK) continues to rise among white people throughout the world and it is necessary to increase the level of attention paid to it from a diagnostic and a preventive point of view.
  • Today, AK must be considered an in situ squamous cell carcinoma and as such, must be managed using one of the available approved therapeutic alternatives.
  • [MeSH-major] Keratosis, Actinic / therapy. Practice Guidelines as Topic. Precancerous Conditions / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Cryotherapy. Curettage. Dermatologic Agents / therapeutic use. Disease Progression. Electrocoagulation. Female. Humans. Italy / epidemiology. Laser Therapy. Male. Middle Aged. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / prevention & control. Phototherapy. Prevalence. Risk Factors. Sunscreening Agents. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907409.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Sunscreening Agents
  •  go-up   go-down


55. Arits AH, van de Weert MM, Nelemans PJ, Kelleners-Smeets NW: Pain during topical photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol; 2010 Dec;24(12):1452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 141 lesions in 108 patients were included, treated from November 2008 until June 2009 with PDT for superficial basal cell carcinoma, Bowen's disease (BD) or actinic keratosis (AK).
  • Factors associated with higher PI-NRS scores were treatment of AK or BD, tumour localization in the head/neck region, patient's age over 70, Fitzpatrick skintype I/II, photosensitizer 5-aminolevulinic acid and use of oral analgesics.

  • MedlinePlus Health Information. consumer health - Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal compilation © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20456543.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Zaballos P, Salsench E, Serrano P, Cuellar F, Puig S, Malvehy J: Studying regression of seborrheic keratosis in lichenoid keratosis with sequential dermoscopy imaging. Dermatology; 2010;220(2):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studying regression of seborrheic keratosis in lichenoid keratosis with sequential dermoscopy imaging.
  • BACKGROUND: Lichenoid keratosis (LK) is a well-described entity that has been proposed to represent a regressive response to a pre-existent epidermal lesion.
  • AIMS: To evaluate the natural evolution of a series of cases showing the intermediate stage of the regression of seborrheic keratosis in LK using sequential dermoscopy imaging over time.
  • MATERIAL AND METHODS: A series of lesions with dermoscopic areas of seborrheic keratosis and LK in the same tumor were consecutively collected for over 3 years at the Dermatology Department of the Hospital de Sant Pau i Santa Tecla, Tarragona, Spain.
  • In 11 cases (50%), the seborrheic keratosis part disappeared completely, and in another 5 cases (22.7%), seborrheic keratosis comprised only 10% of the remaining area.
  • CONCLUSIONS: These dermoscopic study findings support the proposal that LK represents a regressive response to a pre-existent epidermal lesion, in this case seborrheic keratosis.
  • [MeSH-major] Dermoscopy. Keratosis, Seborrheic / diagnosis. Lichen Planus / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Skin Pigmentation

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19996577.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Talghini S, Halimi M, Baybordi H: Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease. Pak J Biol Sci; 2009 Jun 15;12(12):929-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of P27, Ki67 and P53 in squamous cell carcinoma, actinic keratosis and Bowen disease.
  • This study aims at evaluating the expression of P27, Ki67 and P53 in Squamous Cell Carcinoma (SCC), Actinic Keratosis (AK) and Bowen Disease (BD) specimens.
  • In an analytic-descriptive setting, skin biopsy specimens of 45 patients were evaluated in three 15-case groups including BD, AK and SCC specimens.
  • Ki67 was expressed in 0.8, 23.7, 12.3 and 19.3% of the cells in the normal skin, AK, BD and SCC groups, respectively.
  • P27 was positive in 23.4, 26.2, 25.9 and 4.5% of specimens in the normal skin, AK, BD and SCC groups, respectively.
  • P53 expression was detected in 26.6, 41.8 and 54.6% of the assessed cells in the AK, BD and SCC groups, respectively.
  • Based on these results, the quantitative and qualitative (pattern of distribution) evaluation of the expressions of Ki67, P27 and P53 may be helpful in differentiating malignant and premalignant epidermal lesions, particularly in unsatisfactory or fragmented specimens.
  • [MeSH-major] Bowen's Disease / metabolism. Carcinoma, Squamous Cell / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Keratosis, Actinic / metabolism. Ki-67 Antigen / metabolism. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cyclin-Dependent Kinase Inhibitor p27. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Skin / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777788.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


58. Prior SL, Griffiths AP, Lewis PD: A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer. Br J Dermatol; 2009 Nov;161(5):1067-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, they have not been examined in the SCC precursor lesions, Bowen disease or actinic keratosis.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624548.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


59. Situm M, Bulat V, Buljan M, Puljiz Z, Situm V, Bolanca Z: Senile lentigo--cosmetic or medical issue of the elderly population. Coll Antropol; 2010 Apr;34 Suppl 2:85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Senile lentigo--cosmetic or medical issue of the elderly population.
  • Senile lentigo or age spots are hyperpigmented macules of skin that occur in irregular shapes, appearing most commonly in the sun-exposed areas of the skin such as on the face and back of the hands.
  • Senile lentigo is a common component of photoaged skin and is seen most commonly after the age of 50.
  • There are many disscusions on whether senile lentigo represents a melanoma precursor, namely lentigo maligna melanoma and, if there is a need for a regular follow up in cases of multiple lesions.
  • On contrary, some authors believe that senile lentigo represents a precursor of seborrheic keratosis, which does not require a serious medical treatment.
  • However, the observation of the possible association of senile lentigo with the melanoma development makes us cautious in the assessment of this lesion.
  • If the lesion becomes inflammed it may evolve into benign lichenoid keratosis.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302707.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Cosmetics
  •  go-up   go-down


60. Logié A, Dunois-Lardé C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet; 2005 May 1;14(9):1153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mice expressing the transgene developed benign epidermal tumors with no sign of malignancy.
  • These skin lesions had features in common with acanthosis nigricans and other benign human skin tumors, including seborrheic keratosis, one of the most common benign epidermal tumors in humans.
  • We therefore screened a series of 62 cases of seborrheic keratosis for FGFR3 mutations.
  • Our findings directly implicate FGFR3 activation as a major cause of benign epidermal tumors in humans.
  • [MeSH-major] Gene Expression. Keratosis, Seborrheic / genetics. Point Mutation. Protein-Tyrosine Kinases / genetics. Receptors, Fibroblast Growth Factor / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772091.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Fibroblast Growth Factor; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Fgfr3 protein, mouse; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


61. Pribuisiene R, Uloza V, Kupcinskas L: Diagnostic sensitivity and specificity of laryngoscopic signs of reflux laryngitis. Medicina (Kaunas); 2008;44(4):280-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Presence of mucosal lesions of the interarytenoid notch (roughness, hypertrophy, keratosis, granuloma) increases the odds ratio to attribute the patient to the reflux laryngitis patient group 21 times (OR=21.32, 95% CI 4.38-103.93; P<0.001).
  • Mucosal lesions (hypertrophy, keratosis, granuloma) and edema of vocal cords were determined as the most sensitive and rather specific laryngoscopic signs.
  • [MeSH-major] Gastroesophageal Reflux / complications. Laryngitis / diagnosis. Laryngoscopy / methods
  • [MeSH-minor] Adult. Data Interpretation, Statistical. Female. Humans. Laryngeal Edema / diagnosis. Laryngeal Mucosa. Male. Middle Aged. Odds Ratio. ROC Curve. Sensitivity and Specificity. Stroboscopy. Video Recording. Vocal Cords

  • MedlinePlus Health Information. consumer health - GERD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469504.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


62. Tomas D, Kruslin B, Cupic H, Stanimirovic A, Bosnjak B, Lovricevic I, Belicza M: Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol; 2006 Jan;20(1):51-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis.
  • BACKGROUND: Recent investigations consider actinic keratosis (AK) as an earliest visible pattern of squamous cell carcinoma (SCC).
  • We have analysed the expression of apoptosis-related proteins TP53, Bcl-2 and Bax in 30 atrophic and 30 hypertrophic AK cases.
  • RESULTS: Expression of TP53 showed no significant differences between two analysed groups (chi2-test, P = 0.35636) whereas expression of Bcl-2 and Bax protein was significantly higher in atrophic compared to hypertrophic AK (chi2-test, P = 0.01458 and P = 0.00358, respectively).
  • Comparison of Bcl-2 : Bax ratio in two analysed AK showed significantly higher value in hypertrophic compared to atrophic AK (Mann-Whitney U test, P = 0.02272).
  • CONCLUSIONS: Our results may indicate higher resistance of keratinocytes on apoptotic stimuli in hypertrophic compared to atrophic AK.
  • Thus, we suppose that keratinocytes in hypertrophic AK live longer and probably have higher propensity for additional mutations and conversion to overt SCC.
  • [MeSH-major] Keratosis / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405608.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


63. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A high frequency of epidermal p53 clones has been detected in chronically sun-exposed skin.
  • Studies using p53 mutations as a clonality marker have suggested a direct link between actinic keratosis, SCC in situ and invasive SCC.


64. Hauschild A, Popp G, Stockfleth E, Meyer KG, Imberger D, Mohr P, Itschert G, Kaufmann R, Neuber K, Frambach Y, Gollnick H, Brunnert M, Stocker M, Ortland C, Karrer S: Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch. Exp Dermatol; 2009 Feb;18(2):116-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch.
  • BACKGROUND: Photodynamic therapy (PDT) is increasingly used for the treatment of actinic keratosis (AK).
  • OBJECTIVES: To investigate both the efficacy of different application times and the safety of a novel patch (PD P 506 A) containing aminolaevulinic acid in the PDT of mild to moderate AK.
  • Eight weeks after treatment, 86% of the AK lesions (74% of the patients) treated with 4-h patch application showed complete clearance.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Keratosis, Actinic / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18643849.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


65. Neuhaus IM, LeBoit PE, McCalmont TM: Seborrheic keratosis with basal clear cells: a distinctive microscopic mimic of melanoma in situ. J Am Acad Dermatol; 2006 Jan;54(1):132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seborrheic keratosis with basal clear cells: a distinctive microscopic mimic of melanoma in situ.
  • BACKGROUND: We observed seborrheic keratoses with many basilar clear cells, creating a microscopic pattern that mimicked a seborrheic keratosis involved by melanoma in situ.
  • OBJECTIVE: We sought to report a series of these seborrheic keratoses and the immunohistochemical stains used to reach a proper diagnosis.
  • METHODS: We reviewed 9 cases of seborrheic keratosis that had a distinctive pattern of basal clear cells with ample cytoplasm.
  • CONCLUSIONS: We describe a previously uncharacterized pattern of seborrheic keratosis that can microscopically mimic melanoma in situ.
  • Careful conventional microscopy coupled with a panel of immunostains can allow the proper diagnosis to be reached.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies. Antigens, Neoplasm. Diagnosis, Differential. Female. Humans. Immune Sera. Immunoenzyme Techniques. Keratins / immunology. MART-1 Antigen. Male. Middle Aged. Neoplasm Proteins / immunology. Retrospective Studies. S100 Proteins / immunology. Staining and Labeling

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2017 Jun;44(6):600-602 [28401581.001]
  • (PMID = 16384768.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, Neoplasm; 0 / Immune Sera; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


66. Cardoso CL, Freitas P, Taveira LA, Consolaro A: Darier disease: case report with oral manifestations. Med Oral Patol Oral Cir Bucal; 2006 Aug;11(5):E404-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Darier disease: case report with oral manifestations.
  • Darier disease, also known as keratosis follicularis or dyskeratosis follicularis, is a rare autosomal dominant genodermatosis.
  • This paper reports a case of an adult male patient presenting clinical signs of Darier disease in the palatal mucosa and skin on the neck and upper limbs.
  • Intraoral biopsy of the affected area, analysis of family history and evaluation by a multidisciplinary team led to the diagnosis of Darier disease.
  • Dental professionals and pathologists should be aware of these lesions to allow correct diagnosis and proper management of this disease.
  • [MeSH-major] Darier Disease / pathology. Mouth Diseases / pathology

  • Genetic Alliance. consumer health - Darier Disease.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878056.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


67. Ross AH, Kennedy CT, Collins C, Harrad RA: The use of imiquimod in the treatment of periocular tumours. Orbit; 2010 Apr;29(2):83-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two patients were diagnosed with basal cell carcinoma of the eyelid, one patient with actinic keratosis, one with intraepidermal squamous cell carcinoma (Bowen's disease) and one patient had concomitant squamous cell carcinoma and intraepidermal squamous cell carcinoma.
  • In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal squamous cell carcinoma, basal cell carcinoma and squamous cell carcinoma.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Eyelid Neoplasms / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Bowen's Disease / drug therapy. Bowen's Disease / pathology. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Ophthalmic Solutions. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394545.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 99011-02-6 / imiquimod
  •  go-up   go-down


68. Nindl I, Dang C, Forschner T, Kuban RJ, Meyer T, Sterry W, Stockfleth E: Identification of differentially expressed genes in cutaneous squamous cell carcinoma by microarray expression profiling. Mol Cancer; 2006;5:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Three different biopsies of 5 immunosuppressed organ-transplanted recipients each normal skin (all were pooled), actinic keratosis (AK) (two were pooled), and invasive SCC and additionally 5 normal skin tissues from immunocompetent patients were analyzed.
  • Broad coherent patterns in normal skin vs. AK and SCC were observed for 118 genes.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunogenetics. 1994;40(2):129-34 [8026862.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2171-6 [8668343.001]
  • [Cites] Gene. 1996 Sep 26;174(1):129-34 [8863739.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Oct;29(10):1133-7 [9438376.001]
  • [Cites] Cell. 1999 Jan 8;96(1):121-30 [9989503.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):1087-91 [10362121.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6745-50 [10359783.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4746-52 [15570075.001]
  • [Cites] Bone. 2003 Apr;32(4):364-71 [12689679.001]
  • [Cites] J Am Acad Dermatol. 2000 Jan;42(1 Pt 2):11-7 [10607351.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2232-8 [10786689.001]
  • [Cites] Biotechniques. 2000 Aug;29(2):310-3 [10948432.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Immunol Res. 2001;23(2-3):179-91 [11444383.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5195-8 [11526508.001]
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):8-18 [11684447.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):204-9 [11740709.001]
  • [Cites] Eur J Biochem. 2002 Jan;269(1):259-71 [11784320.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2001;47 Online Pub:OL61-72 [11936875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20965-73 [11916966.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] J Cell Physiol. 2002 Aug;192(2):125-30 [12115718.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Br J Dermatol. 2003 Jan;148(1):102-9 [12534602.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Oncogene. 2003 May 15;22(19):2993-3006 [12771951.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Adv Exp Med Biol. 2003;532:91-107 [12908552.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):487-91 [12963914.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1275-88 [12973694.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):317-29 [14724562.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):15711-4 [14966141.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):352-61 [15095299.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:260-4 [15247025.001]
  • [Cites] Mol Cancer. 2002 Nov 12;1:6 [12495447.001]
  • [Cites] Trends Cell Biol. 2004 Aug;14(8):427-34 [15308209.001]
  • [Cites] Cell. 1986 Mar 28;44(6):913-23 [2420469.001]
  • [Cites] Dermatol Surg. 1996 Mar;22(3):217-26 [8599733.001]
  • (PMID = 16893473.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1569867
  •  go-up   go-down


69. Bugatti L, Filosa G: Dermoscopy of lichen planus-like keratosis: a model of inflammatory regression. J Eur Acad Dermatol Venereol; 2007 Nov;21(10):1392-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermoscopy of lichen planus-like keratosis: a model of inflammatory regression.
  • BACKGROUND: Lichen planus-like keratosis (LPLK) or benign lichenoid keratosis is an involuting cutaneous entity where regressing features are the histologic hallmark.
  • Most authors consider LPLK as an heterogeneous spectrum of intraepithelial epidermal or melanocytic lesions, mainly pigmented, involuting by inflammatory regression.
  • All cases were excised and submitted to histopathologic examination and subdivided into three groups according to the early, classic and atrophic subtypes.
  • FE correlates mainly with early/atrophic types, while the FP nearly exclusively with the late atrophic type.
  • The classic dermoscopic features of regressing lesion for LPLK (pigmented granular pattern) apply to the most frequent encountered pigmented atrophic flat type or classic pigmented type, where sometimes regression is advanced or almost complete and no clear diagnosis of a previous benign/malignant - epithelial or melanocytic lesion can often be given.
  • [MeSH-major] Keratosis / pathology. Lichen Planus / pathology
  • [MeSH-minor] Adult. Aged. Dermoscopy. Disease Progression. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958847.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


70. Lipozenčić J, Bukvić Mokos Z: Dermatologic lasers in the treatment of aging skin. Acta Dermatovenerol Croat; 2010;18(3):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major clinical features of aging skin include xerosis, laxity, wrinkles, slackness, and the occurrence of benign neoplasms such as seborrheic keratoses and cherry angiomas.
  • Photoaging is characterized by dryness (roughness), actinic keratoses, irregular pigmentation (freckling, lentigines, guttate hypomelanosis, persistent hyperpigmentation), wrinkling, stellate pseudoscars, elastosis (fine nodularity and/or coarseness), inelasticity, telangiectasia, venous lakes, purpura (easy bruising), comedones (maladie de Favre et Racouchot) and sebaceous hyperplasia.

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887699.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Croatia
  •  go-up   go-down


71. Pivarcsi A, Müller A, Hippe A, Rieker J, van Lierop A, Steinhoff M, Seeliger S, Kubitza R, Pippirs U, Meller S, Gerber PA, Liersch R, Buenemann E, Sonkoly E, Wiesner U, Hoffmann TK, Schneider L, Piekorz R, Enderlein E, Reifenberger J, Rohr UP, Haas R, Boukamp P, Haase I, Nürnberg B, Ruzicka T, Zlotnik A, Homey B: Tumor immune escape by the loss of homeostatic chemokine expression. Proc Natl Acad Sci U S A; 2007 Nov 27;104(48):19055-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we demonstrate that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways.
  • Compared with healthy skin, CCL27 mRNA and protein expression was progressively lost in transformed keratinocytes of actinic keratoses and basal and squamous cell carcinomas.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Cytotoxicity, Immunologic. Down-Regulation. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / metabolism. Humans. Keratinocytes / metabolism. Melanoma, Experimental / genetics. Melanoma, Experimental / immunology. Melanoma, Experimental / metabolism. Mice. Mice, Inbred C57BL. Photosensitivity Disorders / immunology. Photosensitivity Disorders / metabolism. Precancerous Conditions / immunology. Precancerous Conditions / metabolism. Proto-Oncogene Proteins p21(ras) / physiology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / physiology. Signal Transduction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5 [10588729.001]
  • [Cites] Cancer Gene Ther. 2006 Apr;13(4):393-405 [16224496.001]
  • [Cites] J Immunol. 2000 Apr 1;164(7):3465-70 [10725697.001]
  • [Cites] Annu Rev Immunol. 2000;18:217-42 [10837058.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1567-79 [11583982.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7552-5 [11606393.001]
  • [Cites] Nat Med. 2002 Feb;8(2):157-65 [11821900.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):477-85 [11900233.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):175-84 [11913068.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1189-96 [12133939.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]
  • [Cites] Immunol Rev. 2002 Oct;188:97-113 [12445284.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):201-2 [12676577.001]
  • [Cites] J Virol. 2003 Jul;77(13):7393-400 [12805438.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4420-5 [12907614.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):68-76 [15047149.001]
  • [Cites] FEBS Lett. 2004 Jun 1;567(1):63-6 [15165894.001]
  • [Cites] J Immunol. 1989 May 15;142(10):3714-25 [2785562.001]
  • [Cites] J Natl Cancer Inst. 1989 Dec 20;81(24):1893-904 [2593166.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2840-7 [2183932.001]
  • [Cites] Cell. 1990 May 4;61(3):407-17 [2185890.001]
  • [Cites] Prog Clin Biol Res. 1992;376:61-84 [1528930.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):897-908 [9670968.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):447-58 [15542429.001]
  • [Cites] Oncologist. 2005 May;10(5):345-56 [15851793.001]
  • [Cites] FASEB J. 2005 Nov;19(13):1836-8 [16170018.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):573-8 [10662803.001]
  • (PMID = 18025475.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCL27 protein, human; 0 / Ccl27 protein, mouse; 0 / Chemokine CCL27; 0 / Neoplasm Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras)
  • [Other-IDs] NLM/ PMC2141907
  •  go-up   go-down


72. Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, Millar SE, Pear WS, Parmacek MS: Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res; 2006 Aug 1;66(15):7438-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report that DNMAML1 mice display hyperplastic epidermis and spontaneously develop cutaneous squamous cell carcinoma (SCC) as well as dysplastic precursor lesions, actinic keratoses.
  • Mice expressing epidermal DNMAML1 display enhanced accumulation of nuclear beta-catenin and cyclin D1 in suprabasilar keratinocytes and in lesional cells from SCCs, which was also observed in human cutaneous SCC.
  • The demonstration that inhibition of canonical Notch signaling in mice leads to spontaneous formation of SCC and recapitulates the disease in humans yields fundamental insights into the pathogenesis of SCC and provides a unique in vivo animal model to examine the pathobiology of cutaneous SCC and for evaluating novel therapies.


73. Cowen EW, Nguyen JC, Miller DD, McShane D, Arron ST, Prose NS, Turner ML, Fox LP: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol; 2010 Jan;62(1):31-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underlying diagnoses included graft-versus-host disease, HIV, and Wegener granulomatosis.
  • Signs of chronic phototoxicity and accelerated photoaging included erythema, actinic keratoses, and lentigo formation.


74. Fatmi Z, Azam I, Ahmed F, Kazi A, Gill AB, Kadir MM, Ahmed M, Ara N, Janjua NZ, Core Group for Arsenic Mitigation in Pakistan: Health burden of skin lesions at low arsenic exposure through groundwater in Pakistan. Is river the source? Environ Res; 2009 Jul;109(5):575-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of skin lesions of arsenic was estimated for complex survey design, using surveyfreq and surveylogistic options of SAS 9.1 software.The prevalence of definitive cases i.e. hyperkeratosis of both palms and soles, was 3.4 per 1000 and suspected cases i.e. any sign of arsenic skin lesions (melanosis and/or keratosis), were 13.0 per 1000 among > or = 15-year-old persons in the district.

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419713.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical
  • [Investigator] Panhwar SA; Tahir A; Ahmad T; Dil A; Shahbaz A; Ahmed S
  •  go-up   go-down


75. Scheinfeld NS: Actinic keratoses. Skinmed; 2007 Jul-Aug;6(4):188-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses.
  • [MeSH-major] Keratosis. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Lentigo / diagnosis. Male. Precancerous Conditions. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618171.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Corbalán-Vélez R, Ruiz-Macia JA, Brufau C, López-Lozano JM, Martínez-Barba E, Carapeto FJ: [Clear cells in cutaneous squamous cell carcinoma]. Actas Dermosifiliogr; 2009 May;100(4):307-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced or established SCCs and SCCs associated with Bowen disease contained a larger proportion of clear cells.
  • We defined 2 histological patterns: a) clear cells around the keratin pearls of SCCs arising from pre-existing actinic keratosis and with indirect signs of human papilloma virus infection in hair follicles; and b) clear cells that simulate adnexal differentiation in lesions arising on pre-existing Bowen disease lesions.
  • The presence of clear cells is suggestive of adnexal differentiation; however, in the majority of cases, their presence is due to infiltration of normal adnexal structures by the cells of pagetoid Bowen disease.


77. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev; 2005 Aug;26(5):662-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physiological and pharmacological actions of 1,25-(OH)(2)D(3) in various systems, along with the detection of VDR in target cells, have indicated potential therapeutic applications of VDR ligands in inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, actinic keratosis, seborrheic dermatitis, photoaging), osteoporosis (postmenopausal and steroid-induced osteoporosis), cancers (prostate, colon, breast, myelodysplasia, leukemia, head and neck squamous cell carcinoma, and basal cell carcinoma), secondary hyperparathyroidism, and autoimmune diseases (systemic lupus erythematosus, type I diabetes, multiple sclerosis, and organ transplantation).

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798098.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D
  • [Number-of-references] 284
  •  go-up   go-down


78. Benatiya AI, Bouayed MA, Touiza E, Daoudi K, Bhalil S, Elmesbahi I, Tahri H: [Tyrosinemia type II. Case report]. Bull Soc Belge Ophtalmol; 2005;(296):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tyrosinemia type II or Richner-Hanhart syndrome is a rare hereditary disease characterized by the association of pseudoherpetiform corneal ulcerations and palmoplantar hyperkeratosis.
  • We report the case of a 12 year-old young man presenting a superficial punctate keratitis and a corneal dystrophy in both eyes, associated with a palmoplantar hyperkeratosis.
  • Tyrosinemia type II is an autosomal recessive disease, due to an enzymatic deficit in tyrosine aminotransferase.
  • The diagnosis is based on the clinic and high level of serum and urinary tyrosine as well as of its urinary metabolites.
  • This disease must be suspected in all cases of dentritic keratitis not reacting on the antiviral treatment, and more especially if it is associated with cutaneous lesions such as palmo-plantar keratosis.
  • [MeSH-major] Tyrosinemias / diagnosis

  • Genetic Alliance. consumer health - BabysFirstTest - Tyrosinemia Type II.
  • Genetic Alliance. consumer health - Tyrosinemia.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050420.001).
  • [ISSN] 0081-0746
  • [Journal-full-title] Bulletin de la Société belge d'ophtalmologie
  • [ISO-abbreviation] Bull Soc Belge Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 42HK56048U / Tyrosine
  •  go-up   go-down


79. Micali G, Lacarrubba F, Dinotta F, Massimino D, Nasca MR: Treating skin cancer with topical cream. Expert Opin Pharmacother; 2010 Jun;11(9):1515-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TAKE HOME MESSAGE: Topical pharmacotherapy represents an option for treatment of actinic keratoses and selected basal cell carcinomas.
  • Moreover, preliminary reports indicate imiquimod to be effective for skin or mucosal cancers such as Bowen's disease, erythroplasia of Queyrat and lentigo maligna.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408746.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Retinoids; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


80. Jainkittivong A, Aneksuk V, Langlais RP: Oral mucosal lesions in denture wearers. Gerodontology; 2010 Mar;27(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When analysed by type, traumatic ulcer, denture hyperplasia, frictional keratosis and candidiasis were more common in complete denture wearers, whereas denture-induced stomatitis was more common in partial denture wearers.
  • Frictional keratosis was more common in men than in women.
  • [MeSH-minor] Age Factors. Aged. Atrophy. Candidiasis, Oral / epidemiology. Cheilitis / epidemiology. Denture, Complete / statistics & numerical data. Denture, Partial / statistics & numerical data. Disease. Female. Friction. Humans. Hyperplasia. Leukoedema, Oral / epidemiology. Leukoplakia, Oral / epidemiology. Male. Middle Aged. Mouth Mucosa / pathology. Oral Ulcer / epidemiology. Prevalence. Retrospective Studies. Sex Factors. Stomatitis, Denture / epidemiology. Thailand / epidemiology. Tongue / pathology. Tongue, Fissured / epidemiology


81. Kalisiak MS, Rao J: Photodynamic therapy for actinic keratoses. Dermatol Clin; 2007 Jan;25(1):15-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for actinic keratoses.
  • Actinic keratoses (AKs) are one of the most common conditions that are treated by dermatologists and they have the potential to progress to squamous cell carcinoma if left untreated.
  • This article focuses on practical aspects of PDT in the treatment of AKs, outcomes of relevant clinical trials, and special applications of PDT in transplant recipients and other who are predisposed to AK formation.
  • [MeSH-major] Keratosis / drug therapy. Photochemotherapy. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126738.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 39
  •  go-up   go-down


82. Mann M, Berk DR, Petersen J: Chemowraps as an adjuvant to surgery for patients with diffuse squamous cell carcinoma of the extremities. J Drugs Dermatol; 2008 Jul;7(7):685-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Managing patients with diffuse squamous cell carcinoma (SCC) and actinic damage on their extremities is challenging because SCCs may be ill-defined, confluent, and only amenable to radical surgery.
  • Diffuse actinic keratoses put patients at risk for further malignancies and may be difficult to distinguish from SCCs.
  • An experience using chemowraps, a novel approach involving weekly 5-fluorouracil (5-FU) 5% cream under Unna wraps to reduce actinic keratoses, as an adjuvant to surgery is described.
  • Before chemowraps were applied, biopsies and clinical lymph node examinations were performed to confirm the diagnosis of SCC.
  • Patients were informed that chemowraps represent an off-label use of 5-FU to reduce actinic keratoses as an adjuvant to definitive surgery for SCCs.
  • RESULTS: Three patients were referred for diffuse actinic damage and biopsy-proven SCCs on the legs.
  • CONCLUSIONS: Chemowraps may be useful in managing patients with diffuse SCCs in fields of severe actinic damage on the extremities.
  • As an adjuvant to surgery, chemowraps may treat surrounding actinic keratoses, help define tumor borders, and minimize the extent of surgery required.
  • [MeSH-minor] Administration, Cutaneous. Aged. Chemotherapy, Adjuvant. Female. Humans. Keratosis / drug therapy. Leg


83. Gerster JF, Lindstrom KJ, Miller RL, Tomai MA, Birmachu W, Bomersine SN, Gibson SJ, Imbertson LM, Jacobson JR, Knafla RT, Maye PV, Nikolaides N, Oneyemi FY, Parkhurst GJ, Pecore SE, Reiter MJ, Scribner LS, Testerman TL, Thompson NJ, Wagner TL, Weeks CE, Andre JD, Lagain D, Bastard Y, Lupu M: Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production. J Med Chem; 2005 May 19;48(10):3481-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro results reported herein and the in vivo results reported previously led to the discovery of imiquimod, 26, which was developed as a topical agent and has been approved for the treatment of genital warts, actinic keratosis, and superficial basal cell carcinoma.

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887957.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antiviral Agents; 0 / Imidazoles; 0 / Interferon Inducers; 0 / Quinolines; 9008-11-1 / Interferons; 99011-02-6 / imiquimod
  •  go-up   go-down


84. Pastar Z, Lipozencić J, Rados J, Stajminger G: Regressing seborrheic keratosis - clinically and dermoscopically mimicking a regressing melanoma. Acta Dermatovenerol Croat; 2007;15(1):24-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regressing seborrheic keratosis - clinically and dermoscopically mimicking a regressing melanoma.
  • The diagnosis of seborrheic keratosis is a clinical diagnosis.
  • In a certain percentage of cases, differential diagnosis between seborrheic keratosis and malignant melanoma is difficult.
  • We describe a case of regressing seborrheic keratosis simulating malignant melanoma.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Melanoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Dermoscopy. Diagnosis, Differential. Humans. Male

  • Genetic Alliance. consumer health - Keratosis, seborrheic.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433176.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


85. Kwon EJ, Kish LS, Jaworsky C: The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol; 2009 Sep;61(3):522-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three lesions showed keratin-filled endophytic epithelial-lined invaginations, one with a coexistent actinic keratosis.
  • To our knowledge, diffuse eruptions of epidermal invaginations, ectatic follicular infundibula, and follicular infundibular cysts have not been reported previously with sorafenib, although they are well known to occur with epidermal growth factor receptor inhibitor therapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700018.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


86. Stockfleth E: Topical management of actinic keratosis and field cancerisation. G Ital Dermatol Venereol; 2009 Aug;144(4):459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical management of actinic keratosis and field cancerisation.
  • Actinic keratosis (AK) is a squamous cell carcinoma of the epidermis in situ.
  • In around 10% of all patients with AK and in approximately 30% of patients with additional immune suppression an invasive squamous cell carcinoma of the skin is subsequently observed highlighting that AKs should be identified and treated early.
  • The hallmarks and characteristic features of non-melanoma skin cancer have been defined histologically: histopathology allows the differentiation based on a small tissue sample and remains the gold standard for diagnosis.
  • For all therapies the objective is to cure lesions, both clinically and histologically, by the destruction of mutated keratinocytes and to reduce the numbers of AK lesions with the minimum of pain, scarring and recurrence.
  • Recurrence of a lesion (which by definition affects the same site) is often the result of incomplete removal of clinically apparent AK lesions after treatment or the presence of subclinical lesions that were not identified and removed.
  • AK lesions can be treated individually or, if the lesions are numerous in an area of sun-damaged skin the whole area should be treated to remove subclinical lesions as well as those clinically visible (field-directed therapy).Overall the treatment choice is based on several factors, including location and number of lesions, growth and morphology, area of sun-damaged skin, age, lifestyle, and factors related to previous treatment or patient history.
  • [MeSH-major] Keratosis, Actinic / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755950.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


87. Ming M, Han W, Maddox J, Soltani K, Shea CR, Freeman DM, He YY: UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes. Oncogene; 2010 Jan 28;29(4):492-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] UVB-induced ERK/AKT-dependent PTEN suppression promotes survival of epidermal keratinocytes.
  • As compared with normal skin, PTEN levels are reduced in human actinic keratosis, a precancerous skin lesion caused by solar UV.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Phys Physiol Meas. 1991 Nov;12(4):311-25 [1778030.001]
  • [Cites] Phys Med Biol. 1991 Mar;36(3):299-328 [1645473.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] Nat Genet. 1997 May;16(1):64-7 [9140396.001]
  • [Cites] Nat Genet. 1997 Aug;16(4):333-4 [9241266.001]
  • [Cites] Genes Dev. 1998 Feb 15;12(4):502-13 [9472019.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Jun;22(2):152-6 [9598803.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2006-11 [15598755.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1521-31 [16247443.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3680-8 [16682958.001]
  • [Cites] Neoplasma. 2006;53(4):328-32 [16830061.001]
  • [Cites] Cell. 2006 Nov 3;127(3):481-93 [17081972.001]
  • [Cites] Cell Death Differ. 2007 Feb;14(2):218-29 [16676006.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10343-50 [17974977.001]
  • [Cites] Photochem Photobiol. 2008 Jan-Feb;84(1):69-74 [18173704.001]
  • [Cites] Adv Exp Med Biol. 2008;624:283-95 [18348464.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3752-8 [18483258.001]
  • [Cites] J Invest Dermatol. 2000 Feb;114(2):277-80 [10651986.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23919-26 [10787418.001]
  • [Cites] J Invest Dermatol. 2000 Sep;115(3):427-34 [10951279.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):493-7 [11179477.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):993-8 [11035045.001]
  • [Cites] Development. 2002 Sep;129(17):4159-70 [12163417.001]
  • [Cites] Sci STKE. 2003 Jan 28;2003(167):RE2 [12554854.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):318-27 [12569555.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):30652-60 [12788938.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):23-35 [14681688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1725-30 [14747659.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):533-43 [15009741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Sep;71(9):3363-6 [4530308.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):373-8 [2839537.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • (PMID = 19881543.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA014599-34; United States / NCRR NIH HHS / RR / UL1 RR024999; United States / NIEHS NIH HHS / ES / R01 ES016936-01A2; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / CA014599-33; United States / NCI NIH HHS / CA / P30 CA014599-330014; United States / NCRR NIH HHS / RR / RR024999-03; United States / NCRR NIH HHS / RR / RR024999-01; United States / NCI NIH HHS / CA / P30 CA014599-34; United States / NCRR NIH HHS / RR / UL1 RR024999-03; United States / NCI NIH HHS / CA / CA014599-340014; United States / NIEHS NIH HHS / ES / R01 ES016936; United States / NCI NIH HHS / CA / CA014599-330014; United States / NCRR NIH HHS / RR / UL1 RR024999-02; United States / NCRR NIH HHS / RR / UL1 RR024999-01; United States / NCI NIH HHS / CA / CA014599-32; United States / NCI NIH HHS / CA / P30 CA014599-33; United States / NCI NIH HHS / CA / P30 CA014599-340014; United States / NIEHS NIH HHS / ES / ES016936-01A2; United States / NCRR NIH HHS / RR / UL1RR024999; United States / NCI NIH HHS / CA / P30 CA014599-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.48 / Pten protein, mouse; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS147984; NLM/ PMC2813408
  •  go-up   go-down


88. Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R: Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? Dermatology; 2010;221(3):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To our knowledge, few cases of actinic keratoses and variants of squamous cell carcinomas associated with sorafenib have been published.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20720388.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


89. Caekelbergh K, Annemans L, Lambert J, Roelandts R: Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol; 2006 Oct;155(4):784-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma.
  • BACKGROUND: Various effective therapeutic options are currently available for the treatment of actinic keratosis (AK) and basal cell carcinoma (BCC), but none is perfect.
  • OBJECTIVES: To evaluate the cost-effectiveness of a recent approach, methyl aminolaevulinate-based photodynamic therapy (MAL-PDT; Metvix; Galderma, Lausanne, Switzerland) in AK and BCC.
  • The time horizon was 1 year for AK and 5 years for BCC.
  • The comparators were cryotherapy in AK and excision surgery in BCC.
  • RESULTS: MAL-PDT is a more expensive treatment compared with cryotherapy for AK.
  • CONCLUSIONS: The results suggest that MAL-PDT is a cost-effective intervention in AK taking a 1-year time horizon, if society is willing to pay euro1.50 per day of response, and that MAL-PDT is better value for money than excision in BCC, taking a 5-year time horizon.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / economics. Keratosis / economics. Photochemotherapy / economics. Skin Neoplasms / economics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Dermatol. 2007 Jun;156(6):1393-4 [17535242.001]
  • [CommentIn] Br J Dermatol. 2007 Jun;156(6):1392; author reply 1393 [17535240.001]
  • (PMID = 16965429.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


90. Melnikova VO, Ananthaswamy HN: Cellular and molecular events leading to the development of skin cancer. Mutat Res; 2005 Apr 1;571(1-2):91-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apoptosis-resistant keratinocytes undergo clonal expansion that eventually leads to formation of actinic keratoses and squamous cell carcinomas.
  • [MeSH-minor] Animals. Disease Progression. Genes, p53. Humans. Mice. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15748641.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5 P30 ES07784; United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 46523; United States / NCI NIH HHS / CA / U01 CA105345
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 136
  •  go-up   go-down


91. Greenberg HL, Cohen JL, Rosen T, Orengo I: Severe reaction to 5% imiquimod cream with excellent clinical and cosmetic outcomes. J Drugs Dermatol; 2007 Apr;6(4):452-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imiquimod, an immune response modifier approved for the treatment of external genital warts, actinic keratoses, and superficial basal cell carcinoma, can induce a severe local inflammatory response.
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / adverse effects. Adjuvants, Immunologic / chemistry. Administration, Topical. Adult. Aged. Aged, 80 and over. Cheilitis / chemically induced. Cheilitis / drug therapy. Female. Humans. Keratosis / chemically induced. Keratosis / drug therapy. Male. Middle Aged. Ointments. Time Factors. Treatment Outcome

  • Hazardous Substances Data Bank. Imiquimod .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668546.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


92. Choi MJ, Kim HS, Kim HO, Song KY, Park YM: A case of lymphomatoid keratosis. Ann Dermatol; 2010 May;22(2):219-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of lymphomatoid keratosis.
  • Lymphomatoid keratosis (LK) is considered to be a rare variant of cutaneous lymphoid hyperplasia, with epidermotropism.
  • Histopathologically, the specimen showed hyperkeratosis, parakeratosis, acanthosis and Pautrier's micro-abscess in the epidermis, and a lichenoid infiltration of lymphocytes in the dermis, which expressed both B cell and T cell lineage on the immune-histochemical staining.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 2007 Jan;143(1):53-9 [17224542.001]
  • [Cites] Arch Dermatol. 2006 Dec;142(12):1561-6 [17178981.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1312-3 [9382576.001]
  • [Cites] J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):283-5 [10642687.001]
  • [Cites] J Dermatol. 2003 May;30(5):417-9 [12773809.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1264-5 [12452884.001]
  • [Cites] J Cutan Pathol. 2002 May;29(5):291-4 [12100630.001]
  • [Cites] Arch Dermatol. 1997 Feb;133(2):231, 234 [9041840.001]
  • (PMID = 20548920.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883432
  • [Keywords] NOTNLM ; Cutaneous lymphoid hyperplasia / Epidermotropism / Lymphomatoid keratosis
  •  go-up   go-down


93. Raasch BA, Buettner PG: Knowledge and perceptions about sunburn and solar keratoses in Australia. Australas J Dermatol; 2008 Aug;49(3):142-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knowledge and perceptions about sunburn and solar keratoses in Australia.
  • An omnibus telephone survey of 1200 adult Australians determined self-reported prevalence of and attitudes to sunburn and sunspots, knowledge of the term solar keratosis and prevalence of skin checks.
  • While 29% reported currently having sunspots, 69% had never heard of the term solar keratosis, 30% had never had a skin check and 28% had their last skin check more than 12 months ago.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Keratosis / epidemiology. Sunburn / epidemiology

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18638221.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


94. Kopera D, Kerl H: Detection and treatment of preclinical actinic keratoses (PAK). J Dtsch Dermatol Ges; 2010 Sep;8(9):693-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and treatment of preclinical actinic keratoses (PAK).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Facial Dermatoses / diagnosis. Keratosis, Actinic / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Precancerous Conditions / diagnosis

  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20561117.001).
  • [ISSN] 1610-0387
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] eng; ger
  • [Publication-type] Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


95. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, Katsamas J: Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol; 2009 Jun;60(6):934-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
  • BACKGROUND: There is a need for improved medical approaches to the treatment of actinic keratosis.
  • Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic keratosis.
  • OBJECTIVE: Assess the efficacy and safety of ingenol mebutate (formerly PEP005) gel at 3 dosing regimens for the treatment of actinic keratosis.
  • METHODS: Patients with non-facial actinic keratoses applied vehicle gel for 3 days, ingenol mebutate gel, 0.025% for 3 days, or ingenol mebutate gel, 0.05% for 2 or 3 days, with an 8-week follow-up period.
  • RESULTS: All 3 active treatments were significantly more effective than vehicle at clearing actinic keratosis lesions, with a dose response observed.
  • The median percentage reduction in baseline actinic keratosis lesions for patients treated with ingenol mebutate gel ranged from 75% to 100% compared with 0% for vehicle gel (P < .0001 vs vehicle).
  • CONCLUSIONS: Short-course, field-directed therapy with ingenol mebutate gel for actinic keratoses on non-facial sites seems to be effective with a favorable safety profile and potential benefits over topical agents that require a more prolonged course of treatment.
  • [MeSH-major] Diterpenes / administration & dosage. Keratosis, Actinic / drug therapy

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467365.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-ingenyl angelate; 0 / Diterpenes; 0 / Gels; 0 / Pharmaceutical Vehicles; 0 / Plant Extracts
  •  go-up   go-down


96. Saraceno R, Teoli M, Chimenti S: Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. Clin Ther; 2008 Jul;30(7):1324-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His current medication regimen was hydroxyurea (500 mg BID), iron (525 mg QD), and folic acid (15 mg QD) for the myeloproliferative disease and the associated anemia; spironolactone (25 mg BID) and furosemide (20 mg BID) for the complications of cirrhosis; allopurinol (100 mg QD) to treat gout; and theophylline (250 mg QD) for chronic bronchitis.
  • The patient presented with several actinic keratoses, squamous cell carcinomas, and multiple keratoacanthomas, one of which was pigmented.
  • Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the myeloproliferative disorder.

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18691992.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


97. Zhang Q, Wang WH, Zhao M, Shen L, Cheng JH, Zhang BY, Li LF: Clinical and pathological study of lichen-planus-like keratosis in China. J Dermatol; 2006 Jul;33(7):457-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological study of lichen-planus-like keratosis in China.
  • Lichen-planus-like keratosis is usually diagnosed pathologically; rarely, a definitive diagnosis can be made grossly in the clinic.
  • Only a few cases of lichen-planus-like keratosis have been reported in China.
  • The purpose of this study was to investigate the clinical and pathological features of lichen-planus-like keratosis in China.
  • Fifty cases of lichen-planus-like keratosis patients diagnosed pathologically during a 5-year period in our clinic were analyzed.
  • Only one case (2%) was considered to be lichen-planus-like keratosis clinically.
  • By hematoxylin and eosin staining, solar lentigo and solar elastosis could be found in 68% and 32% of lichen-planus-like keratosis lesions, respectively.
  • Lichen-planus-like keratosis is not uncommon in clinical practice in China, the diagnosis of lichen-planus-like keratosis should be made by a combination of clinical manifestations and pathological changes.
  • It is better to classify lichen-planus-like keratosis as a benign skin tumor.
  • More attention should be paid to lichen-planus-like keratosis in China.
  • [MeSH-major] Keratosis / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. China / epidemiology. Diagnosis, Differential. Female. Humans. Lichen Planus / diagnosis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848817.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


98. Batchelor RJ, Stables GI, Stringer MR: Successful treatment of scalp actinic keratoses with photodynamic therapy using ambient light. Br J Dermatol; 2007 Apr;156(4):779-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of scalp actinic keratoses with photodynamic therapy using ambient light.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Keratosis / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Scalp Dermatoses / drug therapy

  • MedlinePlus Health Information. consumer health - Dandruff, Cradle Cap, and Other Scalp Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17286635.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


99. Jorizzo J, Weiss J, Vamvakias G: One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol; 2006 Feb;5(2):133-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study.
  • Topical fluorouracil is currently approved for the treatment of actinic keratosis (AK) and is often used prior to or following cryosurgery as interval therapy in patients with severe AK lesions.
  • Efficacy was determined by evaluating AK reduction and clearance (complete lack of AK lesions in the treatment area) at 4 weeks follow-up.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cryosurgery. Fluorouracil / therapeutic use. Keratosis / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16485881.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


100. Saita V, Azzolina A, Galia A, Fraggetta F: Schwannoma of the epiglottis: case report focusing on clinico-pathological aspects. Acta Otorhinolaryngol Ital; 2005 Dec;25(6):378-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein we present a further case of a schwannoma of the epiglottis, occurring in a 62-year-old with a clinical history of a cutaneous malignant melanoma and laryngeal glottic keratosis.
  • Authors focus on the diagnostic and therapeutic options for this unusual lesion and discuss the differential diagnosis of the spindle cell proliferation of the larynx.
  • [MeSH-major] Epiglottis / pathology. Epiglottis / surgery. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Neurilemmoma / pathology. Neurilemmoma / surgery. Voice Disorders / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endoscopy / methods. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Voice Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):773-4 [10793366.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Sep-Oct;65(5):310-3 [14730191.001]
  • [Cites] Br J Dermatol. 2004 Mar;150(3):531-6 [15030338.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):666-71 [10435926.001]
  • [Cites] Clin Radiol. 1997 Jan;52(1):75-6 [9022589.001]
  • [Cites] Eur J Radiol. 1995 Nov;21(1):61-6 [8654462.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):515-23 [2195959.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):469-72 [3721890.001]
  • [Cites] Hong Kong Med J. 2004 Apr;10(2):131-3 [15075434.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000 Dec;257(10):555-7 [11195036.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Mar;127(3):325-8 [11255480.001]
  • [Cites] J Laryngol Otol. 1999 Apr;113(4):346-8 [10474670.001]
  • [Cites] Laryngoscope. 2002 Jun;112(6):997-1002 [12160298.001]
  • [Cites] Ear Nose Throat J. 2002 Sep;81(9):662-3 [12353445.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):153-70 [11812937.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2003 Feb;120(1):40-4 [12717316.001]
  • [Cites] Acta Otolaryngol. 2003 Jan;123(1):86-90 [12625580.001]
  • (PMID = 16749608.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639895
  •  go-up   go-down






Advertisement